Ligand Pharmaceuticals Incorporated
Buy, Hold or Sell?

Let's analyse Ligand together

Penke I guess you are interested in Ligand Pharmaceuticals Incorporated. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ligand Pharmaceuticals Incorporated. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ligand Pharmaceuticals Incorporated

I send you an email if I find something interesting about Ligand Pharmaceuticals Incorporated.

Quick analysis of Ligand (30 sec.)

What can you expect buying and holding a share of Ligand? (30 sec.)

How much money do you get?

$0.79

When do you have the money?

1 year

How often do you get paid?

10.0%

What is your share worth?

Current worth

$39.67

Expected worth in 1 year

$45.59

How sure are you?

72.5%

+ What do you gain per year?

Total Gains per Share

$6.71

Return On Investment

9.3%

For what price can you sell your share?

Current Price per Share

$72.52

Expected price per share

$68.14 - $94.57

How sure are you?

50%

1. Valuation of Ligand (5 min.)

Live pricePrice per Share (EOD)

$72.52

Book Value per Share

$39.67

Intrinsic Value Per Share

$-81.74 - $-18.54

Total Value Per Share

$-42.07 - $21.13

My calculation of the intrinsic value of Ligand is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($0.67) 3Y: ($0.89) TTM: ($-0.07)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($-0.07) 3Y: ($-0.18) TTM: ($-0.03)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$0.84	$2.79	$-0.23 - $2.40
2	$-1.01	$4.39	$-3.15 - $1.23
3	$-5.27	$4.85	$-6.07 - $0.06
4	$-11.65	$4.24	$-8.99 - $-1.12
5	$-19.90	$2.63	$-11.91 - $-2.29
6	$-29.79	$0.07	$-14.83 - $-3.47
7	$-41.10	$-3.38	$-17.75 - $-4.64
8	$-53.64	$-7.66	$-20.66 - $-5.81
9	$-67.24	$-12.74	$-23.58 - $-6.99
10	$-81.74	$-18.54	$-26.50 - $-8.16

2. Growth of Ligand (5 min.)

Is Ligand growing?

	Current year	Previous year	Grow	Grow %
How rich?	$702.3m	$548.4m	$121.2m	18.1%

How much money is Ligand making?

	Current year	Previous year	Grow	Grow %
Making money	$12.4m	-$7.6m	$20m	161.3%
Net Profit Margin	32.5%	-15.9%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Ligand (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#74 / 1016

Most Revenue
#192 / 1016

Most Profit
#91 / 1016

Most Efficient
#46 / 1016

What can you expect buying and holding a share of Ligand? (5 min.)

Welcome investor! Ligand's management wants to use your money to grow the business. In return you get a share of Ligand.

What can you expect buying and holding a share of Ligand?

First you should know what it really means to hold a share of Ligand. And how you can make/lose money.

Speculation

The Price per Share of Ligand is $72.52. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Ligand.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ligand, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $39.67. Based on the TTM, the Book Value Change Per Share is $1.48 per quarter. Based on the YOY, the Book Value Change Per Share is $-3.16 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.20 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Ligand.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	1.03	1.4%	0.69	1.0%	-0.47	-0.6%	1.67	2.3%	1.26	1.7%
Usd Book Value Change Per Share	2.09	2.9%	1.48	2.0%	-3.16	-4.4%	0.65	0.9%	0.93	1.3%
Usd Dividend Per Share	0.00	0.0%	0.20	0.3%	0.08	0.1%	0.06	0.1%	0.03	0.0%
Usd Total Gains Per Share	2.09	2.9%	1.68	2.3%	-3.08	-4.3%	0.71	1.0%	0.96	1.3%
Usd Price Per Share	71.42	-	69.25	-	63.13	-	71.66	-	73.17	-
Price to Earnings Ratio	17.38	-	36.02	-	71.57	-	16.84	-	39.10	-
Price-to-Total Gains Ratio	34.22	-	209.39	-	16.67	-	87.03	-	69.57	-
Price to Book Ratio	1.80	-	1.84	-	302.52	-	61.90	-	35.62	-
Price-to-Total Gains Ratio	34.22	-	209.39	-	16.67	-	87.03	-	69.57	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	72.52
Number of shares	13

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.20	0.06
Usd Book Value Change Per Share	1.48	0.65
Usd Total Gains Per Share	1.68	0.71
Gains per Quarter (13 shares)	21.80	9.21
Gains per Year (13 shares)	87.21	36.83

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	10	77	77	3	34	27
2	20	154	164	6	68	64
3	31	231	251	9	102	101
4	41	308	338	12	136	138
5	51	385	425	14	170	175
6	61	462	512	17	204	212
7	71	539	599	20	237	249
8	82	616	686	23	271	286
9	92	693	773	26	305	323
10	102	770	860	29	339	360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	3.0	1.0	0.0	75.0%	7.0	5.0	0.0	58.3%	10.0	10.0	0.0	50.0%	25.0	15.0	0.0	62.5%	43.0	75.0	0.0	36.4%
Book Value Change Per Share	4.0	0.0	0.0	100.0%	10.0	2.0	0.0	83.3%	15.0	5.0	0.0	75.0%	29.0	11.0	0.0	72.5%	60.0	58.0	0.0	50.8%
Dividend per Share	2.0	0.0	2.0	50.0%	4.0	0.0	8.0	33.3%	4.0	0.0	16.0	20.0%	4.0	0.0	36.0	10.0%	12.0	0.0	106.0	10.2%
Total Gains per Share	4.0	0.0	0.0	100.0%	10.0	2.0	0.0	83.3%	15.0	5.0	0.0	75.0%	29.0	11.0	0.0	72.5%	63.0	55.0	0.0	53.4%

Fundamentals of Ligand

About Ligand Pharmaceuticals Incorporated

https://www.ligand.com
Biotechnology
58
555 Heritage Drive, Jupiter, FL, United States, 33458
Google Maps Bing Maps

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Fundamental data was last updated by Penke on 2024-04-11 13:18:03.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ligand Pharmaceuticals Incorporated.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Ligand earns for each $1 of revenue.

Above 10% is considered healthy but always compare Ligand to the Biotechnology industry mean.
A Net Profit Margin of 64.7% means that $0.65 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 64.7%. The company is making a huge profit. +2
The TTM is 32.5%. The company is making a huge profit. +2

Trends

Current period		Compared to		+/-
MRQ	64.7%	TTM	32.5%	+32.3%
TTM	32.5%	YOY	-15.9%	+48.3%
TTM	32.5%	5Y	75.4%	-43.0%
5Y	75.4%	10Y	82.1%	-6.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	64.7%	-197.2%	+261.9%
TTM	32.5%	-210.4%	+242.9%
YOY	-15.9%	-279.3%	+263.4%
5Y	75.4%	-436.8%	+512.2%
10Y	82.1%	-599.3%	+681.4%

Measures how much net profit Ligand earns for each $1 of revenue.

Revenue is the amount of profit Ligand generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Ligand earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Ligand to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Ligand makes more profit. This shows the investor how efficiently Ligand is operating in general and compared to other companies in the same industry. Ligand operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Ligand. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Ligand is 0.65. This means that Ligand earned $0.65 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -197.2%.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Ligand with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Ligand sells assets (profit will increase while costs remain the same).
It won’t show what part of Ligand is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Ligand

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Ligand = 18,188
Total revenue MRQ Ligand = 28,101
$18,188 / $28,101 = 0.65 or 64.7%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Ligand is using its assets to generate profit.

Above 5% is considered healthy but always compare Ligand to the Biotechnology industry mean.
2.2% Return on Assets means that Ligand generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 2.2%. Using its assets, the company is less efficient in making profit.
The TTM is 1.5%. Using its assets, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	2.2%	TTM	1.5%	+0.7%
TTM	1.5%	YOY	8.8%	-7.3%
TTM	1.5%	5Y	3.9%	-2.4%
5Y	3.9%	10Y	3.7%	+0.2%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.2%	-13.6%	+15.8%
TTM	1.5%	-12.9%	+14.4%
YOY	8.8%	-11.9%	+20.7%
5Y	3.9%	-14.2%	+18.1%
10Y	3.7%	-16.2%	+19.9%

Shows how efficient Ligand is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Ligand to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Ligand is using its resources to generate profit. If the return on assets (2.2%) from Ligand are higher than the Biotechnology mean (-13.6%) that means Ligand is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Ligand is 2.2%. This means the company generated $0.02 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.6%.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Ligand

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Ligand = 18,188
Total assets MRQ (balance sheet) from Ligand = 833,064
18,188 / 833,064 = 0.02 or 2.2%

ROA is an important ratio as it will tell you how effectively Ligand is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Ligand is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Ligand to the Biotechnology industry mean.
2.6% Return on Equity means Ligand generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 2.6%. Using its investors money, the company is inefficient in making profit. -1
The TTM is 1.9%. Using its investors money, the company is inefficient in making profit. -1

Trends

Current period		Compared to		+/-
MRQ	2.6%	TTM	1.9%	+0.7%
TTM	1.9%	YOY	11.3%	-9.4%
TTM	1.9%	5Y	5.8%	-4.0%
5Y	5.8%	10Y	7.3%	-1.5%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.6%	-17.0%	+19.6%
TTM	1.9%	-16.1%	+18.0%
YOY	11.3%	-15.4%	+26.7%
5Y	5.8%	-20.0%	+25.8%
10Y	7.3%	-21.1%	+28.4%

Shows how efficient Ligand is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Ligand to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Ligand is 2.6%. This means Ligand generated $0.03 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -17.0%.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if Ligand existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Ligand

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Ligand = 18,188
Shareholders equity (balance sheet) MRQ Ligand = 700,913
18,188 / 700,913 = 0.03 or 2.6%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Ligand Pharmaceuticals Incorporated.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Ligand is operating .

Measures how much profit Ligand makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Ligand to the Biotechnology industry mean.
An Operating Margin of 3.4% means the company generated $0.03 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 3.4%. The company is operating less efficient.
The TTM is 14.8%. The company is operating less efficient.

Trends

Current period		Compared to		+/-
MRQ	3.4%	TTM	14.8%	-11.4%
TTM	14.8%	YOY	-12.4%	+27.2%
TTM	14.8%	5Y	-91.9%	+106.8%
5Y	-91.9%	10Y	-21.5%	-70.5%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	3.4%	-286.1%	+289.5%
TTM	14.8%	-224.4%	+239.2%
YOY	-12.4%	-288.4%	+276.0%
5Y	-91.9%	-475.2%	+383.3%
10Y	-21.5%	-624.7%	+603.2%

Measures how efficient Ligand is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Ligand to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Ligand is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Ligand is 3.4%. This means that Ligand earned $0.03 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -286.1%.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Ligand

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Ligand = -3,358
Total revenue MRQ Ligand = 28,101
$-3,358 / $28,101 = 0.03 or 3.4%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Ligand is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 1.12 means that the operating costs are $1.12 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 1.119. The company is inefficient in keeping operating costs low. -1
The TTM is 0.961. The company is less efficient in keeping operating costs low.

Trends

Current period		Compared to		+/-
MRQ	1.119	TTM	0.961	+0.159
TTM	0.961	YOY	1.150	-0.190
TTM	0.961	5Y	0.977	-0.017
5Y	0.977	10Y	0.773	+0.204

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.119	2.997	-1.878
TTM	0.961	3.247	-2.286
YOY	1.150	3.766	-2.616
5Y	0.977	5.675	-4.698
10Y	0.773	7.857	-7.084

Measures how efficient Ligand is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Ligand to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Ligand is 111.9%. This means that Ligand earned $1.12 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.00.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Ligand

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(1,664 +29,795) \ 28,101 = 1.12

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Ligand Pharmaceuticals Incorporated.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Ligand is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 14.15 means the company has $14.15 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 14.148. The company is very able to pay all its short-term debts. +2
The TTM is 10.136. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	14.148	TTM	10.136	+4.012
TTM	10.136	YOY	3.058	+7.078
TTM	10.136	5Y	15.127	-4.991
5Y	15.127	10Y	10.057	+5.070

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	14.148	3.930	+10.218
TTM	10.136	4.251	+5.885
YOY	3.058	5.436	-2.378
5Y	15.127	6.045	+9.082
10Y	10.057	6.363	+3.694

Measures if Ligand is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Ligand if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Ligand is 14.15. This means Ligand has $14.15 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.93.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Ligand

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
237,429 \ 16,782) = 14.15

The current ratio measures if Ligand is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Ligand is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Ligand does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Ligand is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Ligand is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Ligand to the Biotechnology industry mean.
A Quick Ratio of 21.27 means the company can pay off $21.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 21.271. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 15.632. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	21.271	TTM	15.632	+5.640
TTM	15.632	YOY	4.485	+11.146
TTM	15.632	5Y	19.467	-3.836
5Y	19.467	10Y	12.859	+6.608

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	21.271	3.629	+17.642
TTM	15.632	4.065	+11.567
YOY	4.485	5.397	-0.912
5Y	19.467	5.993	+13.474
10Y	12.859	6.277	+6.582

1.4. Solvency of Ligand Pharmaceuticals Incorporated.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Ligand assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Ligand to Biotechnology industry mean.
A Debt to Asset Ratio of 0.16 means that Ligand assets are financed with 15.7% credit (debt) and the remaining percentage (100% - 15.7%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 0.157. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.154. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.157	TTM	0.154	+0.002
TTM	0.154	YOY	0.244	-0.090
TTM	0.154	5Y	0.336	-0.181
5Y	0.336	10Y	0.423	-0.087

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.157	0.332	-0.175
TTM	0.154	0.334	-0.180
YOY	0.244	0.268	-0.024
5Y	0.336	0.366	-0.030
10Y	0.423	0.390	+0.033

Measures how much % of Ligand assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Ligand than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Ligand to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Ligand is 0.16. This means means that Ligand is financed with 15.7% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 393.0%.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Ligand has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Ligand

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
130,707 \ 833,064 = 15.7% or 0.16.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Ligand is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Ligand to the Biotechnology industry mean.
A Debt to Equity ratio of 18.6% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ligand Pharmaceuticals Incorporated:

The MRQ is 0.186. The company is very able to pay all its debts with equity. +2
The TTM is 0.184. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.186	TTM	0.184	+0.002
TTM	0.184	YOY	0.325	-0.140
TTM	0.184	5Y	0.552	-0.368
5Y	0.552	10Y	1.207	-0.654

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.186	0.381	-0.195
TTM	0.184	0.390	-0.206
YOY	0.325	0.334	-0.009
5Y	0.552	0.434	+0.118
10Y	1.207	0.466	+0.741

Measures if Ligand is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Ligand is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Ligand is 0.19. This means that Ligand can pay off $0.19 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.38.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Ligand

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
130,707 \ 700,913 = 0.19 or 18.6%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Ligand Pharmaceuticals Incorporated

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ligand generates.

Above 15 is considered overpriced but always compare Ligand to the Biotechnology industry mean.
A PE ratio of 17.38 means the investor is paying $17.38 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ligand Pharmaceuticals Incorporated:

The EOD is 17.649. Based on the earnings, the company is fair priced.
The MRQ is 17.381. Based on the earnings, the company is fair priced.
The TTM is 36.021. Based on the earnings, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	17.649	MRQ	17.381	+0.268
MRQ	17.381	TTM	36.021	-18.640
TTM	36.021	YOY	71.565	-35.545
TTM	36.021	5Y	16.839	+19.182
5Y	16.839	10Y	39.102	-22.263

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	17.649	-2.315	+19.964
MRQ	17.381	-2.560	+19.941
TTM	36.021	-2.664	+38.685
YOY	71.565	-4.122	+75.687
5Y	16.839	-6.258	+23.097
10Y	39.102	-6.108	+45.210

Measures how much money you pay for each share for every $1 in earnings Ligand generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Ligand to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Ligand is 17.38. This means the investor is paying $17.38 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.56.
What is the trend?
The trend is important because it shows you how Ligand is performing over time. The most recent quarter might be important if Ligand released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ligand up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Ligand

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 17,676 = EPS
PE ratio MRQ = 17.38

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ligand Pharmaceuticals Incorporated:

The EOD is -7.521. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is -7.407. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is -270.305. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-7.521	MRQ	-7.407	-0.114
MRQ	-7.407	TTM	-270.305	+262.899
TTM	-270.305	YOY	19.206	-289.511
TTM	-270.305	5Y	-50.360	-219.945
5Y	-50.360	10Y	-5.706	-44.654

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-7.521	-3.067	-4.454
MRQ	-7.407	-3.251	-4.156
TTM	-270.305	-3.545	-266.760
YOY	19.206	-5.595	+24.801
5Y	-50.360	-8.315	-42.045
10Y	-5.706	-8.708	+3.002

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Ligand is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 1.80 means the investor is paying $1.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ligand Pharmaceuticals Incorporated:

The EOD is 1.828. Based on the equity, the company is underpriced. +1
The MRQ is 1.800. Based on the equity, the company is underpriced. +1
The TTM is 1.841. Based on the equity, the company is underpriced. +1

Trends

Current period		Compared to		+/-
EOD	1.828	MRQ	1.800	+0.028
MRQ	1.800	TTM	1.841	-0.040
TTM	1.841	YOY	302.515	-300.675
TTM	1.841	5Y	61.899	-60.058
5Y	61.899	10Y	35.616	+26.283

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	1.828	1.905	-0.077
MRQ	1.800	2.111	-0.311
TTM	1.841	2.095	-0.254
YOY	302.515	2.836	+299.679
5Y	61.899	3.443	+58.456
10Y	35.616	3.794	+31.822

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ligand Pharmaceuticals Incorporated.

3.1. Institutions holding Ligand Pharmaceuticals Incorporated

Institutions are holding 94.122% of the shares of Ligand Pharmaceuticals Incorporated.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	BlackRock Inc	16.7312	0.0054	2962314	121230	4.267
2023-12-31	Vanguard Group Inc	10.5986	0.0029	1876514	24653	1.3313
2023-12-31	HHG PLC	7.5862	0.0572	1343154	1281	0.0955
2023-12-31	Macquarie Group Ltd	5.5766	0.0815	987354	-4464	-0.4501
2023-12-31	State Street Corporation	3.7745	0.0023	668284	45029	7.2248
2023-12-31	Dimensional Fund Advisors, Inc.	3.735	0.0138	661298	46906	7.6345
2023-12-31	Stephens Inv Mgmt Group LLC	3.7245	0.6885	659434	191870	41.0361
2023-12-31	Villere St Denis J & Co Llc	2.4176	2.5177	428051	-10110	-2.3074
2023-12-31	Geode Capital Management, LLC	2.0944	0.0028	370815	18194	5.1596
2023-12-31	Pacer Advisors, INC.	1.8397	0.0658	325727	121049	59.1412
2023-12-31	abrdn PLC	1.6403	0.045	290418	-29711	-9.2809
2023-12-31	Rice Hall James & Associates, LLC	1.5589	1.1415	276008	-6953	-2.4572
2023-12-31	Chicago Capital, LLC	1.3076	0.5954	231511	-128834	-35.753
2023-12-31	Cardinal Capital Management Llc	1.2535	0.7282	221927	15528	7.5233
2023-12-31	Northern Trust Corp	1.2413	0.0028	219780	-101	-0.0459
2023-12-31	Amvescap Plc.	1.2138	0.0037	214901	-3886	-1.7762
2023-12-31	Impax Asset Management Group PLC	1.159	0.0588	205208	20888	11.3325
2023-12-31	Morgan Stanley - Brokerage Accounts	1.1251	0.0013	199194	4187	2.1471
2023-12-31	William Blair Investment Management, LLC	1.0581	0.0389	187342	27549	17.2404
2023-12-31	Deutsche Bank AG	1.05	0.0068	185897	49668	36.4592
Total		70.6859	6.0603	12515131	+503973	+4.0%

3.2. Funds holding Ligand Pharmaceuticals Incorporated

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-03-28	iShares Core S&P Small-Cap ETF	6.2528	0.1007	1107084	-4084	-0.3675
2023-12-31	Janus Henderson Triton D	5.0714	0.9404	897906	0	0
2023-12-31	Janus Henderson US SMID Cap Growth	5.0714	0.9444	897906	0	0
2023-12-31	Macquarie US Small Cap Core Equity	4.1847	0.7079	740914	0	0
2024-02-29	Delaware Small Cap Core I	4.1363	0.7894	732343	205	0.028
2024-02-29	Vanguard Total Stock Mkt Idx Inv	2.8306	0.0026	501174	0	0
2024-02-29	Vanguard Small Cap Index	2.4117	0.0241	427005	3992	0.9437
2024-03-28	iShares Russell 2000 ETF	2.3236	0.0459	411406	198	0.0482
2023-12-31	Stephens SMID Select Growth	2.1769	0.6851	385419	105426	37.6531
2023-12-31	Janus Henderson US Small Cap Growth	1.8714	0.7764	331341	0	0
2023-12-31	Janus Henderson Venture D	1.8714	0.7711	331341	0	0
2023-12-31	Vanguard Explorer Inv	1.7073	0.101	302279	79846	35.8967
2024-02-29	Vanguard Small Cap Value Index Inv	1.6462	0.0435	291471	998	0.3436
2023-12-31	Stephens Small Cap Growth	1.5316	1.0431	271176	87197	47.3951
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.3668	0.0188	242002	152	0.0628
2024-01-31	Impax Small Cap Institutional	1.159	2.2481	205208	0	0
2023-12-31	Impax US Small Cap Strategy Composite	1.159	2.1552	205208	20888	11.3325
2024-03-28	iShares S&P Small-Cap 600 Value ETF	1.1403	0.2043	201902	-2005	-0.9833
2024-02-29	DWS Small Cap Core S	1.0731	1.9533	190000	0	0
2024-01-31	Fidelity Small Cap Index	0.9582	0.05	169653	2840	1.7025
Total		49.9437	13.6053	8842738	+295653	+3.3%

3.3. Insider Transactions

Insiders are holding 5.928% of the shares of Ligand Pharmaceuticals Incorporated.

Date	Owner	Type	Amount	Price
2024-03-05	Stephen L Sabba	SELL	1893	74.3
2024-02-28	Octavio Espinoza	SELL	140	88.46
2023-09-22	Todd C Davis	BUY	4000	59.38
2023-05-16	John W Kozarich	SELL	4444	77.2
2023-05-10	Stephen L Sabba	SELL	6408	77.13
2023-05-08	John W Kozarich	SELL	6408	76.56

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Ligand Pharmaceuticals Incorporated compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	2.087	1.481	+41%	-3.165	+252%	0.652	+220%	0.933	+124%
Book Value Per Share	-	-	39.669	37.678	+5%	30.977	+28%	40.111	-1%	27.203	+46%
Current Ratio	-	-	14.148	10.136	+40%	3.058	+363%	15.127	-6%	10.057	+41%
Debt To Asset Ratio	-	-	0.157	0.154	+2%	0.244	-36%	0.336	-53%	0.423	-63%
Debt To Equity Ratio	-	-	0.186	0.184	+1%	0.325	-43%	0.552	-66%	1.207	-85%
Dividend Per Share	-	-	-	0.196	-100%	0.082	-100%	0.056	-100%	0.028	-100%
Eps	-	-	1.027	0.692	+48%	-0.471	+146%	1.666	-38%	1.259	-18%
Free Cash Flow Per Share	-	-	-2.411	-0.067	-97%	1.693	-242%	0.584	-513%	0.672	-459%
Free Cash Flow To Equity Per Share	-	-	-2.110	-0.912	-57%	-2.204	+4%	-2.884	+37%	-0.628	-70%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	-18.543	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-81.736	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	2.794	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	0.844	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	4.850	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-5.273	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	2.632	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-19.904	-	-	-	-	-	-	-	-
Market Cap	1283988356.000	+2%	1264512526.000	1231478635.500	+3%	1117754622.198	+13%	1294573154.107	-2%	1488044305.178	-15%
Net Profit Margin	-	-	0.647	0.325	+99%	-0.159	+125%	0.754	-14%	0.821	-21%
Operating Margin	-	-	0.034	0.148	-77%	-0.124	+465%	-0.919	+2811%	-0.215	+733%
Operating Ratio	-	-	1.119	0.961	+17%	1.150	-3%	0.977	+15%	0.773	+45%
Pb Ratio	1.828	+2%	1.800	1.841	-2%	302.515	-99%	61.899	-97%	35.616	-95%
Pe Ratio	17.649	+2%	17.381	36.021	-52%	71.565	-76%	16.839	+3%	39.102	-56%
Price Per Share	72.520	+2%	71.420	69.250	+3%	63.131	+13%	71.660	0%	73.171	-2%
Price To Free Cash Flow Ratio	-7.521	-2%	-7.407	-270.305	+3549%	19.206	-139%	-50.360	+580%	-5.706	-23%
Price To Total Gains Ratio	34.745	+2%	34.218	209.388	-84%	16.666	+105%	87.030	-61%	69.570	-51%
Quick Ratio	-	-	21.271	15.632	+36%	4.485	+374%	19.467	+9%	12.859	+65%
Return On Assets	-	-	0.022	0.015	+46%	0.088	-75%	0.039	-44%	0.037	-41%
Return On Equity	-	-	0.026	0.019	+38%	0.113	-77%	0.058	-56%	0.073	-65%
Total Gains Per Share	-	-	2.087	1.677	+24%	-3.083	+248%	0.708	+195%	0.961	+117%
Usd Book Value	-	-	702357000.000	669742000.000	+5%	548464574.500	+28%	727118314.900	-3%	524748132.450	+34%
Usd Book Value Change Per Share	-	-	2.087	1.481	+41%	-3.165	+252%	0.652	+220%	0.933	+124%
Usd Book Value Per Share	-	-	39.669	37.678	+5%	30.977	+28%	40.111	-1%	27.203	+46%
Usd Dividend Per Share	-	-	-	0.196	-100%	0.082	-100%	0.056	-100%	0.028	-100%
Usd Eps	-	-	1.027	0.692	+48%	-0.471	+146%	1.666	-38%	1.259	-18%
Usd Free Cash Flow	-	-	-42680000.000	-1068000.000	-97%	29981750.000	-242%	10436250.000	-509%	13973025.000	-405%
Usd Free Cash Flow Per Share	-	-	-2.411	-0.067	-97%	1.693	-242%	0.584	-513%	0.672	-459%
Usd Free Cash Flow To Equity Per Share	-	-	-2.110	-0.912	-57%	-2.204	+4%	-2.884	+37%	-0.628	-70%
Usd Market Cap	1283988356.000	+2%	1264512526.000	1231478635.500	+3%	1117754622.198	+13%	1294573154.107	-2%	1488044305.178	-15%
Usd Price Per Share	72.520	+2%	71.420	69.250	+3%	63.131	+13%	71.660	0%	73.171	-2%
Usd Profit	-	-	18188000.000	12408750.000	+47%	-7602500.000	+142%	35156400.000	-48%	28114675.000	-35%
Usd Revenue	-	-	28101000.000	32828500.000	-14%	54895500.000	-49%	46736500.000	-40%	39317675.000	-29%
Usd Total Gains Per Share	-	-	2.087	1.677	+24%	-3.083	+248%	0.708	+195%	0.961	+117%
	EOD	+5 -3	MRQ	TTM	+20 -15	YOY	+26 -9	5Y	+12 -23	10Y	+16 -19

4.2. Fundamental Score

Let's check the fundamental score of Ligand Pharmaceuticals Incorporated based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	17.649
Price to Book Ratio (EOD)	Between	0-1	1.828
Net Profit Margin (MRQ)	Greater than	0	0.647
Operating Margin (MRQ)	Greater than	0	0.034
Quick Ratio (MRQ)	Greater than	1	21.271
Current Ratio (MRQ)	Greater than	1	14.148
Debt to Asset Ratio (MRQ)	Less than	1	0.157
Debt to Equity Ratio (MRQ)	Less than	1	0.186
Return on Equity (MRQ)	Greater than	0.15	0.026
Return on Assets (MRQ)	Greater than	0.05	0.022
Total			6/10 (60.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Ligand Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	40.446
Ma 20	Greater than	Ma 50	75.973
Ma 50	Greater than	Ma 100	75.228
Ma 100	Greater than	Ma 200	72.118
Open	Greater than	Close	78.700
Total			4/5 (80.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	833,064
Total Liabilities	130,707
Total Stockholder Equity	700,913

	As reported
Total Liabilities	130,707
Total Stockholder Equity	+ 700,913
Total Assets	= 833,064

Assets

Total Assets	833,064
Total Current Assets	237,429
Long-term Assets	595,635

Total Current Assets

Total Current Assets (as reported)	237,429
Cash And Cash Equivalents	22,954
Short-term Investments	147,355
Net Receivables	39,312
Inventory	23,969
Other Current Assets	3,839
Total Current Assets (calculated)	237,429
+/-	0

Long-term Assets

Long-term Assets (as reported)	595,635
Property Plant Equipment	9,455
Goodwill	103,370
Long Term Investments	48,321
Intangible Assets	366,897
Long-term Assets Other	21,530
Long-term Assets (calculated)	549,573
+/-	46,062

Liabilities & Shareholders' Equity

Total Current Liabilities	16,782
Long-term Liabilities	113,925
Total Stockholder Equity	700,913

Total Current Liabilities

Total Current Liabilities (as reported)	16,782
Short-term Debt	410
Accounts payable	14,894
Other Current Liabilities	256
Total Current Liabilities (calculated)	15,560
+/-	1,222

Long-term Liabilities

Long-term Liabilities (as reported)	113,925
Capital Lease Obligations	6,165
Long-term Liabilities Other	2,961
Long-term Liabilities (calculated)	9,126
+/-	104,799

Total Stockholder Equity

Total Stockholder Equity (as reported)	700,913
Common Stock	18
Retained Earnings	503,016
Accumulated Other Comprehensive Income	-817
Other Stockholders Equity	198,696
Total Stockholder Equity (calculated)	700,913
+/-	0

Other

Capital Stock	18
Cash and Short Term Investments	170,309
Common Stock Shares Outstanding	17,676
Current Deferred Revenue	1,222
Liabilities and Stockholders Equity	833,064
Net Debt	-16,789
Net Invested Capital	700,913
Net Working Capital	220,647
Property Plant and Equipment Gross	31,717
Short Long Term Debt Total	6,165

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2003-12-31

2003-09-30

2003-06-30

2003-03-31

2002-12-31

2002-09-30

2002-06-30

2002-03-31

2001-12-31

2001-09-30

2001-06-30

2001-03-31

2000-12-31

2000-09-30

2000-06-30

2000-03-31

1999-12-31

1999-09-30

1999-06-30

1999-03-31

1998-12-31

1998-09-30

1998-06-30

1998-03-31

1997-12-31

1997-09-30

1997-06-30

1997-03-31

1996-12-31

1996-09-30

1996-06-30

1996-03-31

1995-12-31

1995-09-30

1995-06-30

1995-03-31

1994-12-31

1994-09-30

1994-06-30

1994-03-31

> Total Assets

43,200
36,000
52,100
46,700
45,200
0
93,200
93,600
85,600
76,700
67,600
102,100
96,000
87,800
77,900
107,400
89,500
82,300
125,700
156,000
135,300
123,300
131,700
134,600
129,558
128,992
115,011
113,422
126,220
124,700
116,962
117,473
118,906
127,657
118,026
270,609
241,176
226,932
272,797
301,255
294,189
285,317
288,659
332,466
313,253
301,723
332,466
314,619
288,689
285,932
231,867
326,053
524,810
228,476
211,524
173,278
166,265
160,023
147,191
171,448
139,587
129,176
117,086
141,807
133,620
127,597
112,568
75,559
134,153
127,435
122,466
122,350
111,798
104,594
97,506
104,260
98,363
99,571
101,677
104,713
105,471
99,847
272,283
258,029
263,223
304,762
521,700
533,929
613,438
616,799
600,865
601,585
629,723
640,024
662,337
671,021
754,668
1,858,284
2,105,742
1,260,803
1,913,988
1,801,836
1,547,476
1,469,307
1,185,917
1,242,936
1,247,449
1,362,285
1,295,121
1,256,283
1,273,656
1,301,383
1,105,184
1,076,288
1,051
762,668
811,076
758,105
769,210
833,064

833,064

769,210

758,105

811,076

762,668

1,051

1,076,288

1,105,184

1,301,383

1,273,656

1,256,283

1,295,121

1,362,285

1,247,449

1,242,936

1,185,917

1,469,307

1,547,476

1,801,836

1,913,988

1,260,803

2,105,742

1,858,284

754,668

671,021

662,337

640,024

629,723

601,585

600,865

616,799

613,438

533,929

521,700

304,762

263,223

258,029

272,283

99,847

105,471

104,713

101,677

99,571

98,363

104,260

97,506

104,594

111,798

122,350

122,466

127,435

134,153

75,559

112,568

127,597

133,620

141,807

117,086

129,176

139,587

171,448

147,191

160,023

166,265

173,278

211,524

228,476

524,810

326,053

231,867

285,932

288,689

314,619

332,466

301,723

313,253

332,466

288,659

285,317

294,189

301,255

272,797

226,932

241,176

270,609

118,026

127,657

118,906

117,473

116,962

124,700

126,220

113,422

115,011

128,992

129,558

134,600

131,700

123,300

135,300

156,000

125,700

82,300

89,500

107,400

77,900

87,800

96,000

102,100

67,600

76,700

85,600

93,600

93,200

45,200

46,700

52,100

36,000

43,200

> Total Current Assets

38,600
31,300
46,800
41,600
39,900
0
74,000
73,000
67,800
59,500
50,900
85,400
75,900
64,400
54,800
84,100
63,800
52,300
46,000
78,000
58,300
44,200
54,700
56,700
58,411
55,509
44,036
44,649
57,611
57,581
52,033
53,574
51,150
61,219
48,267
83,753
63,011
56,973
105,862
130,157
124,902
118,811
125,330
172,824
131,701
108,542
172,824
132,967
112,340
113,903
64,527
235,557
427,947
132,183
115,775
109,943
101,899
96,112
85,965
93,929
67,695
69,470
59,895
68,166
50,387
43,402
35,287
37,019
31,296
28,139
26,817
32,230
23,544
21,096
17,434
23,823
17,740
14,570
16,635
24,881
33,403
28,585
198,520
185,158
191,713
196,725
210,324
215,572
133,059
126,563
140,691
163,053
174,701
197,177
224,201
237,021
349,051
1,480,470
1,745,225
870,540
1,567,895
1,442,307
1,183,103
1,123,645
830,727
863,624
857,741
500,559
437,428
410,901
432,082
464,751
276,066
243,784
220
263,601
328,195
276,711
257,761
237,429

237,429

257,761

276,711

328,195

263,601

220

243,784

276,066

464,751

432,082

410,901

437,428

500,559

857,741

863,624

830,727

1,123,645

1,183,103

1,442,307

1,567,895

870,540

1,745,225

1,480,470

349,051

237,021

224,201

197,177

174,701

163,053

140,691

126,563

133,059

215,572

210,324

196,725

191,713

185,158

198,520

28,585

33,403

24,881

16,635

14,570

17,740

23,823

17,434

21,096

23,544

32,230

26,817

28,139

31,296

37,019

35,287

43,402

50,387

68,166

59,895

69,470

67,695

93,929

85,965

96,112

101,899

109,943

115,775

132,183

427,947

235,557

64,527

113,903

112,340

132,967

172,824

108,542

131,701

172,824

125,330

118,811

124,902

130,157

105,862

56,973

63,011

83,753

48,267

61,219

51,150

53,574

52,033

57,581

57,611

44,649

44,036

55,509

58,411

56,700

54,700

44,200

58,300

78,000

46,000

52,300

63,800

84,100

54,800

64,400

75,900

85,400

50,900

59,500

67,800

73,000

74,000

39,900

41,600

46,800

31,300

38,600

Cash And Cash Equivalents

2,100
700
12,100
7,600
13,300
0
12,200
16,000
16,500
11,200
7,000
34,800
22,800
17,700
13,400
62,300
26,100
25,600
24,900
32,800
11,000
8,400
26,700
29,900
23,877
23,157
11,969
9,224
20,972
28,600
17,755
20,741
18,191
25,087
23,177
42,423
12,979
24,248
73,002
59,030
65,558
41,920
46,020
92,310
50,956
32,580
92,310
66,756
49,808
41,615
10,029
158,401
403,911
103,611
69,301
76,812
59,543
29,177
11,801
28,753
4,920
3,549
5,160
16,032
4,044
3,235
3,796
3,346
6,033
3,441
2,251
7,041
9,777
8,885
7,046
12,381
5,037
5,923
3,271
15,979
12,977
22,027
186,588
167,336
165,766
181,609
93,770
200,219
113,201
61,350
124,115
141,048
10,641
172,627
32,739
201,661
51,024
956,927
115,560
718,381
1,428,688
1,332,049
1,099,685
1,011,532
738,811
809,880
456,916
47,619
31,853
21,863
23,430
19,522
14,993
5,280
121
45
282,665
219,041
19,275
22,954

22,954

19,275

219,041

282,665

121

5,280

14,993

19,522

23,430

21,863

31,853

47,619

456,916

809,880

738,811

1,011,532

1,099,685

1,332,049

1,428,688

718,381

115,560

956,927

51,024

201,661

32,739

172,627

10,641

141,048

124,115

61,350

113,201

200,219

93,770

181,609

165,766

167,336

186,588

22,027

12,977

15,979

3,271

5,923

5,037

12,381

7,046

8,885

9,777

7,041

2,251

3,441

6,033

3,346

3,796

3,235

4,044

16,032

5,160

3,549

4,920

28,753

11,801

29,177

59,543

76,812

69,301

103,611

403,911

158,401

10,029

41,615

49,808

66,756

92,310

32,580

50,956

92,310

46,020

41,920

65,558

59,030

73,002

24,248

12,979

42,423

23,177

25,087

18,191

20,741

17,755

28,600

20,972

9,224

11,969

23,157

23,877

29,900

26,700

8,400

11,000

32,800

24,900

25,600

26,100

62,300

13,400

17,700

22,800

34,800

7,000

11,200

16,500

16,000

12,200

13,300

7,600

12,100

700

2,100

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,700
25,300
19,100
17,300
23,805
23,335
19,593
14,439
19,913
16,959
21,669
16,947
19,431
17,469
12,099
21,825
21,004
17,595
13,744
40,004
31,625
43,958
34,387
20,182
38,449
35,694
20,182
20,174
17,897
19,168
21,862
13,447
6,319
11,789
29,091
17,596
30,685
55,819
59,311
51,918
47,684
51,961
39,033
37,200
35,012
28,960
20,273
19,351
10,487
10,000
10,000
10,000
1,517
1,500
1,341
2,767
3,933
4,162
4,968
4,340
12,275
7,490
5,925
7,133
11,459
73,371
93,528
102,791
81,908
45,603
37,535
122,296
148,733
112,404
169,520
181,041
240,864
59,796
996,311
46,191
72,741
60,376
49,856
58,335
32,879
694,724
338,154
363,567
307,354
279,972
299,781
321,586
189,006
142,655
117
167
193,937
190,596
171,227
147,355

147,355

171,227

190,596

193,937

167

117

142,655

189,006

321,586

299,781

279,972

307,354

363,567

338,154

694,724

32,879

58,335

49,856

60,376

72,741

46,191

996,311

59,796

240,864

181,041

169,520

112,404

148,733

122,296

37,535

45,603

81,908

102,791

93,528

73,371

11,459

7,133

5,925

7,490

12,275

4,340

4,968

4,162

3,933

2,767

1,341

1,500

1,517

10,000

10,487

19,351

20,273

28,960

35,012

37,200

39,033

51,961

47,684

51,918

59,311

55,819

30,685

17,596

29,091

11,789

6,319

13,447

21,862

19,168

17,897

20,174

20,182

35,694

38,449

20,182

34,387

43,958

31,625

40,004

13,744

17,595

21,004

21,825

12,099

17,469

19,431

16,947

21,669

16,959

19,913

14,439

19,593

23,335

23,805

17,300

19,100

25,300

35,700

Net Receivables

700
700
800
1,200
700
0
1,300
2,300
1,900
2,000
2,700
3,100
2,300
3,000
3,100
0
0
0
0
0
4,300
2,900
2,300
1,700
2,461
1,938
3,049
12,824
4,911
5,163
6,434
9,798
7,569
13,498
7,001
7,356
17,086
7,689
9,923
19,051
14,185
17,936
30,583
30,847
18,324
21,016
30,847
20,954
20,046
18,667
7,077
11,521
15,659
15,017
15,377
0
10,416
8,682
2,128
12,100
13,912
1,050
2,110
10,400
10,014
9,777
9,876
13,602
9,413
9,067
9,749
12,307
1,992
817
6,588
8,916
8,879
5,534
10,014
6,551
5,681
3,524
6,335
12,956
7,541
11,079
11,347
10,952
16,546
13,653
9,793
17,907
7,057
16,669
15,823
29,473
40,985
42,001
46,976
55,850
26,615
20,259
21,958
41,748
46,777
44,553
32,907
59,064
55,581
62,850
70,714
91,646
41,797
63,272
66
35,038
29,188
27,994
39,187
39,312

39,312

39,187

27,994

29,188

35,038

63,272

41,797

91,646

70,714

62,850

55,581

59,064

32,907

44,553

46,777

41,748

21,958

20,259

26,615

55,850

46,976

42,001

40,985

29,473

15,823

16,669

7,057

17,907

9,793

13,653

16,546

10,952

11,347

11,079

7,541

12,956

6,335

3,524

5,681

6,551

10,014

5,534

8,879

8,916

6,588

817

1,992

12,307

9,749

9,067

9,413

13,602

9,876

9,777

10,014

10,400

2,110

1,050

13,912

12,100

2,128

8,682

10,416

15,377

15,017

15,659

11,521

7,077

18,667

20,046

20,954

30,847

21,016

18,324

30,847

30,583

17,936

14,185

19,051

9,923

7,689

17,086

7,356

7,001

13,498

7,569

9,798

6,434

5,163

4,911

12,824

3,049

1,938

2,461

1,700

2,300

2,900

4,300

3,100

3,000

2,300

3,100

2,700

2,000

1,900

2,300

1,300

700

1,200

800

700

Other Current Assets

35,800
29,900
33,900
32,800
25,900
0
60,500
54,700
49,400
46,300
41,200
47,500
50,800
43,700
38,300
21,800
37,700
26,700
19,600
39,000
1,100
1,100
800
2,100
2,360
1,623
3,180
2,511
6,793
2,340
1,704
2,332
3,131
2,860
2,835
7,308
6,547
2,635
3,188
3,810
3,764
3,245
2,985
17,713
17,076
12,924
17,713
15,750
16,357
25,986
20,520
9,518
78
83
92
15,535
3
11,116
11,298
11
1,179
68,420
57,785
1,364
1,317
1,430
1,342
720
1,151
1,868
1,663
1,344
20,207
17,581
1,015
829
986
848
1,512
959
521
2,217
4,526
4,597
2,408
2,635
10,458
2,768
1,562
2,122
136,664
2,175
641
1,072
1,112
1,514
5,647
12,817
25,339
20,418
9,228
5,672
5,039
4,734
4,940
5,489
3,191
3,822
5,708
6,270
5,161
4,671
4,656
7,804
-107
3,399
2,331
2,770
2,680
3,839

3,839

2,680

2,770

2,331

3,399

-107

7,804

4,656

4,671

5,161

6,270

5,708

3,822

3,191

5,489

4,940

4,734

5,039

5,672

9,228

20,418

25,339

12,817

5,647

1,514

1,112

1,072

641

2,175

136,664

2,122

1,562

2,768

10,458

2,635

2,408

4,597

4,526

2,217

521

959

1,512

848

986

829

1,015

17,581

20,207

1,344

1,663

1,868

1,151

720

1,342

1,430

1,317

1,364

57,785

68,420

1,179

11,298

11,116

15,535

9,518

20,520

25,986

16,357

15,750

17,713

12,924

17,076

17,713

2,985

3,245

3,764

3,810

3,188

2,635

6,547

7,308

2,835

2,860

3,131

2,332

1,704

2,340

6,793

2,511

3,180

1,623

2,360

2,100

800

1,100

39,000

19,600

26,700

37,700

21,800

38,300

43,700

50,800

47,500

41,200

46,300

49,400

54,700

60,500

25,900

32,800

33,900

29,900

35,800

> Long-term Assets

4,600
4,700
5,300
5,100
5,300
0
19,200
20,600
17,800
17,200
16,700
16,700
20,100
23,400
23,100
23,300
25,700
30,000
79,700
78,000
77,000
79,100
77,000
77,900
71,147
73,483
70,975
68,773
68,609
67,119
64,929
63,899
67,756
66,438
69,759
186,856
178,165
169,959
166,935
171,098
169,287
166,506
163,329
0
0
0
159,642
181,652
176,349
172,029
167,340
90,496
96,863
96,293
95,749
63,335
64,366
63,911
61,226
77,519
71,892
59,706
57,191
73,641
83,233
84,195
77,281
38,540
102,857
99,296
95,649
90,120
88,254
83,498
80,072
80,437
80,623
85,001
85,042
79,832
72,068
71,262
73,763
72,871
71,510
108,037
311,376
318,357
480,379
490,236
460,174
438,532
455,022
442,847
438,136
434,000
405,617
377,814
360,517
390,263
346,093
359,529
364,373
345,662
355,190
379,312
389,708
861,726
857,693
845,382
841,574
836,632
829,118
832,504
830
499,067
482,881
481,394
511,449
595,635

595,635

511,449

481,394

482,881

499,067

830

832,504

829,118

836,632

841,574

845,382

857,693

861,726

389,708

379,312

355,190

345,662

364,373

359,529

346,093

390,263

360,517

377,814

405,617

434,000

438,136

442,847

455,022

438,532

460,174

490,236

480,379

318,357

311,376

108,037

71,510

72,871

73,763

71,262

72,068

79,832

85,042

85,001

80,623

80,437

80,072

83,498

88,254

90,120

95,649

99,296

102,857

38,540

77,281

84,195

83,233

73,641

57,191

59,706

71,892

77,519

61,226

63,911

64,366

63,335

95,749

96,293

96,863

90,496

167,340

172,029

176,349

181,652

159,642

163,329

166,506

169,287

171,098

166,935

169,959

178,165

186,856

69,759

66,438

67,756

63,899

64,929

67,119

68,609

68,773

70,975

73,483

71,147

77,900

77,000

79,100

77,000

78,000

79,700

30,000

25,700

23,300

23,100

23,400

20,100

16,700

17,200

17,800

20,600

19,200

5,300

5,100

5,300

4,700

4,600

Property Plant Equipment

3,700
3,700
3,700
3,900
3,800
0
11,300
12,300
12,600
11,900
11,800
11,700
11,700
15,000
15,000
14,900
15,500
15,500
30,400
23,700
22,900
22,500
21,700
20,500
13,045
12,626
11,784
10,972
10,899
10,439
9,748
9,690
10,391
10,238
10,152
9,672
9,229
8,843
9,072
23,501
23,620
23,910
23,844
23,647
23,275
22,927
23,647
22,483
21,758
21,561
21,453
5,551
4,022
3,783
3,434
2,865
2,091
2,024
1,687
12,903
11,195
10,459
9,893
8,522
7,772
7,073
968
559
795
679
678
455
375
644
853
788
758
804
834
867
690
619
551
486
440
405
355
372
567
1,181
1,826
1,819
1,898
1,875
3,526
4,212
4,119
4,187
4,407
5,372
5,575
17,232
16,691
10,353
16,320
17,572
11,426
22,734
25,561
23,883
48,448
32,749
31,403
39,743
47
15,009
15,609
15,154
9,801
9,455

9,455

9,801

15,154

15,609

15,009

39,743

31,403

32,749

48,448

23,883

25,561

22,734

11,426

17,572

16,320

10,353

16,691

17,232

5,575

5,372

4,407

4,187

4,119

4,212

3,526

1,875

1,898

1,819

1,826

1,181

567

372

355

405

440

486

551

619

690

867

834

804

758

788

853

644

375

455

678

679

795

559

968

7,073

7,772

8,522

9,893

10,459

11,195

12,903

1,687

2,024

2,091

2,865

3,434

3,783

4,022

5,551

21,453

21,561

21,758

22,483

23,647

22,927

23,275

23,647

23,844

23,910

23,620

23,501

9,072

8,843

9,229

9,672

10,152

10,238

10,391

9,690

9,748

10,439

10,899

10,972

11,784

12,626

13,045

20,500

21,700

22,500

22,900

23,700

30,400

15,500

14,900

15,000

11,700

11,800

11,900

12,600

12,300

11,300

3,800

3,900

3,700

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,375
347
0
0
700
700
700
700
700
15,213
14,250
14,251
14,894
14,894
14,894
12,238
68,150
12,238
12,238
65,930
65,337
12,238
64,149
63,555
62,961
12,238
61,773
12,238
60,585
285,820
72,360
279,794
276,912
72,207
271,491
72,207
314,543
85,961
307,962
85,961
306,439
303,099
300,609
309,781
305,677
300,861
318,664
326,718
784,992
774,300
762,523
190,183
734,996
720,913
709,570
181
448,128
439,589
431,050
418,613
103,370

103,370

418,613

431,050

439,589

448,128

181

709,570

720,913

734,996

190,183

762,523

774,300

784,992

326,718

318,664

300,861

305,677

309,781

300,609

303,099

306,439

85,961

307,962

85,961

314,543

72,207

271,491

72,207

276,912

279,794

72,360

285,820

60,585

12,238

61,773

12,238

62,961

63,555

64,149

12,238

65,337

65,930

12,238

68,150

12,238

14,894

14,251

14,250

15,213

700

347

5,375

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,346
20,616
0
14,226
0
0
8,207
7,916
8,579
8,387
0
448
413
0
7,417
0
33,996
31,826
29,728
28,118
18,733
17,339
8,345
10,469
6,014
5,137
6,438
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,000
0
0
47,163
48,321

48,321

47,163

3,000

6,438

5,137

6,014

10,469

8,345

17,339

18,733

28,118

29,728

31,826

33,996

7,417

413

448

8,387

8,579

7,916

8,207

14,226

20,616

21,346

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,300
0
0
0
0
44,924
40,163
0
38,641
41,879
37,118
36,358
44,396
148,546
145,862
143,194
140,526
137,857
135,189
132,520
129,852
127,443
144,275
153,773
127,443
146,770
143,268
139,766
84,990
83,083
83,083
0
0
0
0
0
0
5,375
1,838
1,659
482
2,515
13,758
15,833
15,833
12,951
61,544
60,907
57,986
57,437
56,855
56,273
56,580
55,912
55,319
58,816
4,571
4,571
57,076
4,567
4,568
4,568
54,697
8,598
57,539
8,554
8,546
236,283
233,420
25,821
227,620
22,962
220,299
19,526
245,275
20,437
237,210
31,460
31,023
40,008
35,413
20,090
10,381
10,606
10,834
10,979
10,451
10,638
573,120
10,110
10,121
10,267
517
10,182
10,431
10,783
6,602
366,897

366,897

6,602

10,783

10,431

10,182

517

10,267

10,121

10,110

573,120

10,638

10,451

10,979

10,834

10,606

10,381

20,090

35,413

40,008

31,023

31,460

237,210

20,437

245,275

19,526

220,299

22,962

227,620

25,821

233,420

236,283

8,546

8,554

57,539

8,598

54,697

4,568

4,567

57,076

4,571

58,816

55,319

55,912

56,580

56,273

56,855

57,437

57,986

60,907

61,544

12,951

15,833

13,758

2,515

482

1,659

1,838

5,375

83,083

84,990

139,766

143,268

146,770

127,443

153,773

144,275

127,443

129,852

132,520

135,189

137,857

140,526

143,194

145,862

148,546

44,396

36,358

37,118

41,879

38,641

40,163

44,924

39,300

Long-term Assets Other

900
1,000
1,600
1,200
1,500
0
7,900
8,300
5,200
5,300
4,900
5,000
8,400
8,400
8,100
8,400
10,200
14,500
49,300
54,300
54,100
56,600
16,000
57,400
58,102
60,857
59,191
57,801
17,547
56,680
16,540
54,209
20,247
19,842
59,607
177,184
23,074
17,922
17,337
9,740
10,478
10,076
9,633
8,552
14,002
16,481
8,552
12,399
11,323
10,702
60,897
1,862
92,841
92,510
92,315
60,470
62,275
61,887
59,539
59,241
10,365
47,588
46,816
6,543
6,878
34,880
34,071
25,030
2,224
2,114
20,199
17,334
16,130
10,109
1,757
3,292
4,384
4,556
5,320
9,057
1,616
1,514
5,089
4,856
958
206
2,995
2,554
70
603
1,744
1,744
5,028
1,668
2,028
4,859
894
4,829
499
5,843
11,971
18,912
19,179
9,542
17,590
23,631
25,130
18,701
19,949
20,456
3,095
23,252
31,026
37,270
50
14,218
16,377
15,877
20,740
21,530

21,530

20,740

15,877

16,377

14,218

37,270

31,026

23,252

3,095

20,456

19,949

18,701

25,130

23,631

17,590

9,542

19,179

18,912

11,971

5,843

499

4,829

894

4,859

2,028

1,668

5,028

1,744

603

2,554

2,995

206

958

4,856

5,089

1,514

1,616

9,057

5,320

4,556

4,384

3,292

1,757

10,109

16,130

17,334

20,199

2,114

2,224

25,030

34,071

34,880

6,878

6,543

46,816

47,588

10,365

59,241

59,539

61,887

62,275

60,470

92,315

92,510

92,841

1,862

60,897

10,702

11,323

12,399

8,552

16,481

14,002

8,552

9,633

10,076

10,478

9,740

17,337

17,922

23,074

177,184

59,607

19,842

20,247

54,209

16,540

56,680

17,547

57,801

59,191

60,857

58,102

57,400

16,000

56,600

54,100

54,300

49,300

14,500

10,200

8,400

8,100

8,400

5,000

4,900

5,300

5,200

8,300

7,900

1,500

1,200

1,600

1,000

900

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
0
0
0
0
0
0
0
0
0
0
206,423
189,083
129,777
133,595
133,486
123,891
141,007
138,837
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

138,837

141,007

123,891

133,486

133,595

129,777

189,083

206,423

> Total Liabilities

7,300
7,500
19,400
20,400
19,100
0
60,500
65,500
63,400
64,000
59,100
67,600
63,800
64,700
61,800
73,100
66,700
68,600
118,400
167,400
151,100
153,600
176,700
160,200
142,200
145,801
145,351
168,547
164,448
170,328
169,136
175,348
87,884
40,645
37,361
196,594
203,153
199,875
210,201
230,527
233,818
237,318
247,700
407,783
407,209
404,113
407,783
425,038
513,047
524,434
483,057
298,701
455,063
194,244
185,234
144,163
141,731
141,002
145,237
181,813
154,285
141,435
126,583
138,063
131,475
124,941
122,008
80,408
129,144
122,108
120,099
113,704
92,555
86,142
76,271
77,775
67,767
60,303
56,862
55,100
40,470
36,761
229,500
233,621
230,828
235,709
229,519
229,538
221,361
224,883
230,472
230,732
230,945
230,615
237,574
252,374
257,490
1,238,471
1,406,222
699,889
834,014
760,383
696,895
702,075
524,021
547,933
549,625
652,760
549,281
469,766
461,590
479,754
311,992
273,923
234
165,183
164,759
93,213
103,808
130,707

130,707

103,808

93,213

164,759

165,183

234

273,923

311,992

479,754

461,590

469,766

549,281

652,760

549,625

547,933

524,021

702,075

696,895

760,383

834,014

699,889

1,406,222

1,238,471

257,490

252,374

237,574

230,615

230,945

230,732

230,472

224,883

221,361

229,538

229,519

235,709

230,828

233,621

229,500

36,761

40,470

55,100

56,862

60,303

67,767

77,775

76,271

86,142

92,555

113,704

120,099

122,108

129,144

80,408

122,008

124,941

131,475

138,063

126,583

141,435

154,285

181,813

145,237

141,002

141,731

144,163

185,234

194,244

455,063

298,701

483,057

524,434

513,047

425,038

407,783

404,113

407,209

407,783

247,700

237,318

233,818

230,527

210,201

199,875

203,153

196,594

37,361

40,645

87,884

175,348

169,136

170,328

164,448

168,547

145,351

145,801

142,200

160,200

176,700

153,600

151,100

167,400

118,400

68,600

66,700

73,100

61,800

64,700

63,800

67,600

59,100

64,000

63,400

65,500

60,500

19,100

20,400

19,400

7,500

7,300

> Total Current Liabilities

5,100
5,100
7,100
8,100
7,100
0
10,900
15,700
12,800
12,600
11,100
13,800
13,000
13,100
12,200
21,700
14,500
19,700
18,700
26,900
20,000
20,800
19,200
20,700
22,391
24,380
22,455
28,415
22,847
25,455
25,032
31,726
78,315
31,681
27,610
30,535
37,823
35,154
46,290
54,049
57,258
61,470
71,529
216,712
216,216
213,481
216,712
235,211
256,029
268,412
226,415
170,810
340,501
68,058
59,832
50,968
44,311
44,612
51,701
70,614
52,884
48,202
53,047
52,172
41,434
43,598
36,680
33,488
44,570
42,315
42,454
43,643
27,206
30,419
29,879
35,439
33,017
32,571
32,461
28,939
21,005
18,621
18,433
22,779
18,157
17,949
16,253
20,836
12,240
220,347
226,131
227,129
226,995
225,840
231,683
238,868
246,979
632,850
793,344
82,249
186,777
108,985
35,695
17,002
20,438
31,370
42,300
100,111
95,805
52,497
36,297
41,665
42,578
167,853
135
98,810
98,929
29,388
18,866
16,782

16,782

18,866

29,388

98,929

98,810

135

167,853

42,578

41,665

36,297

52,497

95,805

100,111

42,300

31,370

20,438

17,002

35,695

108,985

186,777

82,249

793,344

632,850

246,979

238,868

231,683

225,840

226,995

227,129

226,131

220,347

12,240

20,836

16,253

17,949

18,157

22,779

18,433

18,621

21,005

28,939

32,461

32,571

33,017

35,439

29,879

30,419

27,206

43,643

42,454

42,315

44,570

33,488

36,680

43,598

41,434

52,172

53,047

48,202

52,884

70,614

51,701

44,612

44,311

50,968

59,832

68,058

340,501

170,810

226,415

268,412

256,029

235,211

216,712

213,481

216,216

216,712

71,529

61,470

57,258

54,049

46,290

35,154

37,823

30,535

27,610

31,681

78,315

31,726

25,032

25,455

22,847

28,415

22,455

24,380

22,391

20,700

19,200

20,800

20,000

26,900

18,700

19,700

14,500

21,700

12,200

13,100

13,000

13,800

11,100

12,600

12,800

15,700

10,900

7,100

8,100

7,100

5,100

Short-term Debt

1,200
1,200
1,200
1,300
1,300
0
1,300
2,400
2,700
2,600
2,700
2,600
2,800
2,900
2,900
2,800
2,700
2,800
3,100
3,200
3,300
3,500
3,700
4,100
4,222
4,249
3,900
3,478
2,988
12,234
2,551
5,367
53,131
5,092
8,908
2,087
2,105
6,016
23,228
2,479
2,742
2,756
2,931
2,924
2,976
2,969
2,924
2,745
2,648
2,502
363
37,750
2,151
1,989
1,810
1,528
1,238
978
716
1,829
11,546
11,759
12,097
91
4,574
19,602
15,072
9,859
10,300
10,000
18,030
10,000
2,936
7,306
13,259
14,835
13,212
13,600
12,375
9,109
5,769
2,698
337
334
348
1,638
1,300
934
577
207,363
210,115
212,910
215,748
218,630
221,557
224,529
227,547
210,370
213,144
26,433
26,756
27,087
926
1,242
1,483
1,728
1,029
6,593
7,610
2,320
2,226
46
1,902
117,525
2,393
77,410
77,493
680
497
410

410

497

680

77,493

77,410

2,393

117,525

1,902

2,226

2,320

7,610

6,593

1,029

1,728

1,483

1,242

926

27,087

26,756

26,433

213,144

210,370

227,547

224,529

221,557

218,630

215,748

212,910

210,115

207,363

577

934

1,300

1,638

348

334

337

2,698

5,769

9,109

12,375

13,600

13,212

14,835

13,259

7,306

2,936

10,000

18,030

10,000

10,300

9,859

15,072

19,602

4,574

12,097

11,759

11,546

1,829

716

978

1,238

1,528

1,810

1,989

2,151

37,750

363

2,502

2,648

2,745

2,924

2,969

2,976

2,924

2,931

2,756

2,742

2,479

23,228

6,016

2,105

2,087

8,908

5,092

53,131

5,367

2,551

12,234

2,988

3,478

3,900

4,249

4,222

4,100

3,700

3,500

3,300

3,200

3,100

2,800

2,700

2,800

2,900

2,800

2,600

2,700

2,600

2,700

2,400

1,300

1,200

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
195,908
0
0
0
201,985
207,363
207,363
210,115
212,910
215,748
218,630
221,557
224,529
227,547
210,370
213,144
26,433
26,756
27,087
0
0
0
0
0
0
0
0
0
0
0
114,974
76,600
76,695
76,790
0
0
0

76,790

76,695

76,600

114,974

27,087

26,756

26,433

213,144

210,370

227,547

224,529

221,557

218,630

215,748

212,910

210,115

207,363

201,985

195,908

Accounts payable

1,000
1,300
1,200
2,300
1,000
0
2,100
3,900
1,700
2,400
1,700
4,100
3,500
3,200
3,600
10,700
4,100
7,300
5,500
12,400
7,100
7,600
5,500
5,400
4,822
5,065
4,455
3,827
3,890
4,111
4,418
5,385
7,033
10,026
9,662
11,979
13,441
10,819
17,261
18,691
16,866
20,225
16,719
17,352
14,586
14,276
17,352
15,360
16,325
19,460
16,080
12,259
13,181
10,939
10,448
12,682
10,760
10,290
9,014
14,627
15,641
14,844
14,379
16,945
14,519
13,445
11,339
8,597
13,032
10,628
10,072
11,065
7,893
6,746
6,027
16,277
5,522
4,755
15,579
15,501
3,675
15,532
17,573
22,123
7,442
17,949
3,143
10,422
6,955
2,336
10,937
9,131
6,456
7,124
3,617
9,636
3,407
13,694
1,647
23,383
19,832
14,428
15,100
2,420
3,365
18,931
24,667
3,784
9,469
17,273
7,233
8,403
22,849
33,704
16
5
6,135
16,873
13,110
14,894

14,894

13,110

16,873

6,135

33,704

22,849

8,403

7,233

17,273

9,469

3,784

24,667

18,931

3,365

2,420

15,100

14,428

19,832

23,383

1,647

13,694

3,407

9,636

3,617

7,124

6,456

9,131

10,937

2,336

6,955

10,422

3,143

17,949

7,442

22,123

17,573

15,532

3,675

15,501

15,579

4,755

5,522

16,277

6,027

6,746

7,893

11,065

10,072

10,628

13,032

8,597

11,339

13,445

14,519

16,945

14,379

14,844

15,641

14,627

9,014

10,290

10,760

12,682

10,448

10,939

13,181

12,259

16,080

19,460

16,325

15,360

17,352

14,276

14,586

17,352

16,719

20,225

16,866

18,691

17,261

10,819

13,441

11,979

9,662

10,026

7,033

5,385

4,418

4,111

3,890

3,827

4,455

5,065

4,822

5,400

5,500

7,600

7,100

12,400

5,500

7,300

4,100

10,700

3,600

3,200

3,500

4,100

1,700

2,400

1,700

3,900

2,100

1,000

2,300

1,200

1,300

1,000

Other Current Liabilities

2,900
2,600
4,700
4,500
4,800
0
7,500
9,400
8,400
7,600
6,700
7,100
6,700
7,000
5,700
8,200
7,700
9,600
10,100
11,300
9,600
9,700
10,000
11,200
13,347
15,066
14,100
21,110
7,428
9,110
8,020
12,245
10,736
6,261
5,721
11,786
17,640
14,193
2,299
30,315
35,304
36,108
49,527
196,436
198,654
196,236
43,908
59,587
86,035
103,348
129,577
60,856
323,205
53,166
45,610
34,794
30,349
31,380
39,425
41,893
13,541
9,376
13,945
28,445
16,316
7,888
8,567
13,330
19,934
20,798
13,926
21,338
15,650
15,955
10,135
3,841
13,727
13,764
4,171
4,213
9,476
299
409
172
10,300
-3,721
9,727
-207,084
5,285
5,697
6,584
-118,803
111
86
5,434
4,530
15,950
407,086
576,103
29,147
137,381
66,531
17,439
11,201
11,236
-312
11,200
60,299
53,619
15,757
14,831
22,220
7,324
6,040
98
21,040
15,044
448
916
256

256

916

448

15,044

21,040

6,040

7,324

22,220

14,831

15,757

53,619

60,299

11,200

-312

11,236

11,201

17,439

66,531

137,381

29,147

576,103

407,086

15,950

4,530

5,434

111

-118,803

6,584

5,697

5,285

-207,084

9,727

-3,721

10,300

172

409

299

9,476

4,213

4,171

13,764

13,727

3,841

10,135

15,955

15,650

21,338

13,926

20,798

19,934

13,330

8,567

7,888

16,316

28,445

13,945

9,376

13,541

41,893

39,425

31,380

30,349

34,794

45,610

53,166

323,205

60,856

129,577

103,348

86,035

59,587

43,908

196,236

198,654

196,436

49,527

36,108

35,304

30,315

2,299

14,193

17,640

11,786

5,721

6,261

10,736

12,245

8,020

9,110

7,428

21,110

14,100

15,066

13,347

11,200

10,000

9,700

9,600

11,300

10,100

9,600

7,700

8,200

5,700

7,000

6,700

7,100

6,700

7,600

8,400

9,400

7,500

4,800

4,500

4,700

2,600

2,900

> Long-term Liabilities

2,200
2,400
12,300
12,300
12,000
0
49,600
49,800
50,600
51,400
48,000
53,800
50,800
51,600
49,600
51,400
52,200
48,900
99,700
140,500
131,100
132,800
157,500
139,500
119,809
121,421
122,896
140,132
141,601
144,873
144,104
143,622
9,569
8,964
9,751
166,059
165,330
164,721
163,911
176,478
176,560
175,848
176,171
0
0
0
191,071
189,827
257,018
256,022
256,642
127,891
114,562
126,186
125,402
93,195
97,420
96,390
93,536
111,199
101,401
93,233
73,536
85,891
90,041
81,343
85,328
46,920
84,574
79,793
77,645
70,061
65,349
55,723
46,392
42,336
34,750
27,732
24,401
26,161
19,465
18,140
211,067
210,842
212,671
217,760
213,266
208,702
209,121
4,536
4,341
3,603
3,950
4,775
5,891
13,506
10,511
605,621
612,878
617,640
647,237
651,398
661,200
685,073
503,583
516,563
507,325
552,649
453,476
417,269
425,293
438,089
269,414
106,070
106
66,373
65,830
63,825
84,942
113,925

113,925

84,942

63,825

65,830

66,373

106

106,070

269,414

438,089

425,293

417,269

453,476

552,649

507,325

516,563

503,583

685,073

661,200

651,398

647,237

617,640

612,878

605,621

10,511

13,506

5,891

4,775

3,950

3,603

4,341

4,536

209,121

208,702

213,266

217,760

212,671

210,842

211,067

18,140

19,465

26,161

24,401

27,732

34,750

42,336

46,392

55,723

65,349

70,061

77,645

79,793

84,574

46,920

85,328

81,343

90,041

85,891

73,536

93,233

101,401

111,199

93,536

96,390

97,420

93,195

125,402

126,186

114,562

127,891

256,642

256,022

257,018

189,827

191,071

176,171

175,848

176,560

176,478

163,911

164,721

165,330

166,059

9,751

8,964

9,569

143,622

144,104

144,873

141,601

140,132

122,896

121,421

119,809

139,500

157,500

132,800

131,100

140,500

99,700

48,900

52,200

51,400

49,600

51,600

50,800

53,800

48,000

51,400

50,600

49,800

49,600

12,000

12,300

2,400

2,200

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,975
29,371
0
34,151
0
0
19,406
10,568
6,275
3,725
0
2,339
1,587
194,764
3,071
198,796
200,795
202,951
0
204,653
0
0
0
0
0
0
0
0
595,912
602,839
609,864
616,987
624,209
631,533
638,959
444,432
449,672
454,973
442,293
352,313
315,318
316,889
320,717
176,540
0
0
0
0
0
0
0

176,540

320,717

316,889

315,318

352,313

442,293

454,973

449,672

444,432

638,959

631,533

624,209

616,987

609,864

602,839

595,912

204,653

202,951

200,795

198,796

3,071

194,764

1,587

2,339

3,725

6,275

10,568

19,406

34,151

29,371

29,975

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
0
0
0
0
0
0
0
0
0
0
206,423
189,083
129,777
133,595
133,486
123,891
141,007
138,837
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

138,837

141,007

123,891

133,486

133,595

129,777

189,083

206,423

Warrants

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,628
0
0
32,138
29,563
26,948
24,293
21,597
18,859
16,078
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

16,078

18,859

21,597

24,293

26,948

29,563

32,138

39,628

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,700
2,700
2,700
8,427
8,257
9,716
7,043
6,864
2,700
6,324
6,019
6,714
6,373
6,068
5,979
6,426
5,714
5,045
4,913
7,634
7,533
7,458
7,326
7,307
100,869
101,363
102,227
113,390
112,921
112,582
112,168
80,223
84,672
83,779
81,019
96,676
89,002
84,864
65,192
77,547
81,697
72,999
76,984
38,204
53,337
48,198
45,917
38,909
35,487
29,798
25,854
28,168
28,465
24,861
23,439
25,063
18,314
17,036
16,222
12,142
11,655
14,134
10,315
3,330
4,468
4,536
4,341
3,603
3,950
4,775
5,891
13,506
10,511
9,709
10,039
7,776
25,930
16,700
19,735
61,752
49,920
59,816
48,432
104,713
101,163
101,951
96,937
101,878
76,077
78,955
64,159
56,032
0
52,834
0
0

52,834

56,032

64,159

78,955

76,077

101,878

96,937

101,951

101,163

104,713

48,432

59,816

49,920

61,752

19,735

16,700

25,930

7,776

10,039

9,709

10,511

13,506

5,891

4,775

3,950

3,603

4,341

4,536

4,468

3,330

10,315

14,134

11,655

12,142

16,222

17,036

18,314

25,063

23,439

24,861

28,465

28,168

25,854

29,798

35,487

38,909

45,917

48,198

53,337

38,204

76,984

72,999

81,697

77,547

65,192

84,864

89,002

96,676

81,019

83,779

84,672

80,223

112,168

112,582

112,921

113,390

102,227

101,363

100,869

7,307

7,326

7,458

7,533

7,634

4,913

5,045

5,714

6,426

5,979

6,068

6,373

6,714

6,019

6,324

2,700

6,864

7,043

9,716

8,257

8,427

2,700

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,428
4,475
0
5,742
0
0
3,094
2,916
2,986
3,047
0
3,236
3,189
3,299
3,183
4,882
5,142
2,083
0
0
0
0
0
0
0
0
3,525
3,000
0
0
0
9,614
694
3,761
32,937
21,769
23,340
13,508
64,598
56,812
60,053
63,026
59,095
39,480
42,669
29,832
0
30,010
27,665
0
0

27,665

30,010

29,832

42,669

39,480

59,095

63,026

60,053

56,812

64,598

13,508

23,340

21,769

32,937

3,761

694

9,614

3,000

3,525

2,083

5,142

4,882

3,183

3,299

3,189

3,236

3,047

2,986

2,916

3,094

5,742

4,475

4,428

> Total Stockholder Equity

35,900
28,500
32,700
26,300
26,100
0
32,700
28,100
22,200
12,700
8,500
34,500
32,200
23,100
16,100
34,300
22,800
13,700
7,300
-11,400
-15,800
-30,300
-45,000
-25,600
-12,642
-16,809
-30,340
-55,125
-38,228
-45,628
-52,174
-57,875
31,022
87,012
80,665
74,015
38,023
27,057
62,596
70,728
60,371
47,999
40,959
0
0
0
-75,317
-110,419
-224,358
-238,502
-251,190
27,352
57,402
34,232
26,290
29,115
24,534
19,021
1,954
-10,365
-14,698
-12,259
-9,497
3,744
2,145
2,656
-9,440
-4,849
5,009
5,327
2,367
8,646
19,243
18,452
21,235
26,485
30,596
39,268
44,815
49,613
65,001
64,170
44,372
26,318
35,148
69,053
292,181
304,391
392,077
391,916
370,393
370,853
398,778
409,409
424,763
418,647
497,178
619,813
699,520
560,914
1,079,974
1,041,453
850,581
767,232
661,896
695,003
697,824
709,525
745,840
786,517
812,066
821,629
793,192
802,365
816
597,485
646,317
664,892
665,402
700,913

700,913

665,402

664,892

646,317

597,485

816

802,365

793,192

821,629

812,066

786,517

745,840

709,525

697,824

695,003

661,896

767,232

850,581

1,041,453

1,079,974

560,914

699,520

619,813

497,178

418,647

424,763

409,409

398,778

370,853

370,393

391,916

392,077

304,391

292,181

69,053

35,148

26,318

44,372

64,170

65,001

49,613

44,815

39,268

30,596

26,485

21,235

18,452

19,243

8,646

2,367

5,327

5,009

-4,849

-9,440

2,656

2,145

3,744

-9,497

-12,259

-14,698

-10,365

1,954

19,021

24,534

29,115

26,290

34,232

57,402

27,352

-251,190

-238,502

-224,358

-110,419

-75,317

40,959

47,999

60,371

70,728

62,596

27,057

38,023

74,015

80,665

87,012

31,022

-57,875

-52,174

-45,628

-38,228

-55,125

-30,340

-16,809

-12,642

-25,600

-45,000

-30,300

-15,800

-11,400

7,300

13,700

22,800

34,300

16,100

23,100

32,200

34,500

8,500

12,700

22,200

28,100

32,700

26,100

26,300

32,700

28,500

35,900

Common Stock

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
55
56
56
57
59
60
60
60
67
71
71
72
70
70
73
73
74
74
74
73
73
73
73
73
78
78
78
100
100
101
100
101
101
101
101
119
119
119
119
123
123
124
21
21
21
21
21
21
21
21
21
21
21
21
22
21
21
21
20
20
20
20
20
20
21
21
28
21
21
21
21
21
21
21
21
21
20
19
17
17
16
16
16
16
17
17
17
17
17
17
0
0
17
17
18
18

124

123

119

101

100

101

100

Retained Earnings

-56,000
-63,300
-69,600
-76,100
-81,900
0
-131,900
-140,300
-147,400
-157,400
-165,800
-177,600
-187,700
-198,100
-209,700
-277,700
-291,300
-308,700
-355,000
-395,600
-410,200
-429,200
-447,500
-470,300
-485,304
-501,763
-516,689
-542,725
-554,306
-564,921
-572,665
-585,720
-592,295
-604,541
-611,588
-618,316
-638,636
-650,633
-661,722
-655,778
-668,917
-683,133
-689,922
-794,660
-813,132
-822,056
-794,660
-831,059
-973,288
-989,246
-1,004,166
-862,802
-588,879
-588,698
-587,450
-581,512
-585,445
-591,874
-609,999
-679,626
-684,715
-686,387
-684,584
-681,574
-684,330
-684,608
-696,451
-691,947
-682,460
-683,380
-687,273
-681,771
-680,387
-682,654
-683,822
-682,759
-681,263
-675,173
-673,208
-671,339
-669,242
-667,650
-666,371
-659,315
-658,561
-634,997
-410,458
-402,010
-395,402
-401,165
-428,001
-431,127
-408,398
-402,340
-393,914
-400,924
-327,400
-254,240
-183,914
-229,197
437,140
422,721
407,470
400,105
370,807
392,893
386,192
391,952
410,058
440,783
454,506
449,090
468,838
467,943
467,943
451
492,811
495,101
484,828
503,016

503,016

484,828

495,101

492,811

451

467,943

468,838

449,090

454,506

440,783

410,058

391,952

386,192

392,893

370,807

400,105

407,470

422,721

437,140

-229,197

-183,914

-254,240

-327,400

-400,924

-393,914

-402,340

-408,398

-431,127

-428,001

-401,165

-395,402

-402,010

-410,458

-634,997

-658,561

-659,315

-666,371

-667,650

-669,242

-671,339

-673,208

-675,173

-681,263

-682,759

-683,822

-682,654

-680,387

-681,771

-687,273

-683,380

-682,460

-691,947

-696,451

-684,608

-684,330

-681,574

-684,584

-686,387

-684,715

-679,626

-609,999

-591,874

-585,445

-581,512

-587,450

-588,698

-588,879

-862,802

-1,004,166

-989,246

-973,288

-831,059

-794,660

-822,056

-813,132

-794,660

-689,922

-683,133

-668,917

-655,778

-661,722

-650,633

-638,636

-618,316

-611,588

-604,541

-592,295

-585,720

-572,665

-564,921

-554,306

-542,725

-516,689

-501,763

-485,304

-470,300

-447,500

-429,200

-410,200

-395,600

-355,000

-308,700

-291,300

-277,700

-209,700

-198,100

-187,700

-177,600

-165,800

-157,400

-147,400

-140,300

-131,900

-81,900

-76,100

-69,600

-63,300

-56,000

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
730,966
731,899
732,676
741,889
0
0
751,503
752,952
755,305
758,080
0
723,279
726,758
707,180
718,017
684,355
692,765
697,061
661,850
783,890
755,049
762,576
769,653
777,102
784,376
793,724
798,205
808,765
874,183
883,477
791,114
643,317
619,255
444,587
367,326
295,940
304,404
313,057
318,358
336,621
346,578
358,418
372,969
325,368
335,471
348,994
0
154,424
170,741
0
0

170,741

154,424

348,994

335,471

325,368

372,969

358,418

346,578

336,621

318,358

313,057

304,404

295,940

367,326

444,587

619,255

643,317

791,114

883,477

874,183

808,765

798,205

793,724

784,376

777,102

769,653

762,576

755,049

783,890

661,850

697,061

692,765

684,355

718,017

707,180

726,758

723,279

758,080

755,305

752,952

751,503

741,889

732,676

731,899

730,966

Treasury Stock

-42,280

-42,225

-42,134

-40,521

-36,446

-26,305

-911

-11

Other Stockholders Equity

91,900
91,800
102,300
106,800
112,400
0
169,000
175,500
177,700
179,100
183,300
223,100
230,900
232,200
239,700
326,500
329,600
339,000
380,000
402,000
413,500
419,400
405,100
467,900
495,907
508,198
511,720
513,832
542,308
545,522
546,720
557,326
652,791
721,023
721,723
692,302
676,650
677,666
724,333
726,499
729,267
731,185
730,930
0
0
0
719,041
720,077
747,831
750,636
753,036
890,535
646,321
622,984
613,750
610,517
609,921
610,822
611,749
669,061
669,887
673,915
674,651
684,682
685,331
686,255
686,914
687,046
687,443
688,686
689,619
690,396
699,609
701,085
709,836
714,104
710,672
713,025
715,800
718,017
723,279
726,758
707,180
680,660
684,355
692,765
697,061
701,478
783,890
789,315
794,714
799,216
804,050
808,669
815,321
817,064
824,843
874,183
883,477
791,114
643,317
619,255
444,587
367,326
295,940
304,404
313,057
318,358
336,621
346,578
358,418
822,096
325,368
335,471
349
597,035
154,424
170,741
181,500
198,696

198,696

181,500

170,741

154,424

597,035

349

335,471

325,368

822,096

358,418

346,578

336,621

318,358

313,057

304,404

295,940

367,326

444,587

619,255

643,317

791,114

883,477

874,183

824,843

817,064

815,321

808,669

804,050

799,216

794,714

789,315

783,890

701,478

697,061

692,765

684,355

680,660

707,180

726,758

723,279

718,017

715,800

713,025

710,672

714,104

709,836

701,085

699,609

690,396

689,619

688,686

687,443

687,046

686,914

686,255

685,331

684,682

674,651

673,915

669,887

669,061

611,749

610,822

609,921

610,517

613,750

622,984

646,321

890,535

753,036

750,636

747,831

720,077

719,041

730,930

731,185

729,267

726,499

724,333

677,666

676,650

692,302

721,723

721,023

652,791

557,326

546,720

545,522

542,308

513,832

511,720

508,198

495,907

467,900

405,100

419,400

413,500

402,000

380,000

339,000

329,600

326,500

239,700

232,200

230,900

223,100

183,300

179,100

177,700

175,500

169,000

112,400

106,800

102,300

91,800

91,900

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31
Accounts Payable	14,894	5	8,403	3,784	2,420	23,383	9,636	9,131	10,422	22,123	15,501	16,277	11,065	8,597	16,945	14,627	12,682	12,259	17,352	17,352	18,691	11,979	5,385	3,827	5,400	12,400	10,700	4,100	3,900	2,300
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	-817	-1	-917	-801	-216	-1,024	2,486	2,743	4,903	4,953	2,914	-4,881	-4,771	31	513	81	9	-481	229	-41,097	-66	-43	-678	-2,030	-4,100	-17,800	-14,500	-11,000	-7,100	-4,400
Additional Paid In Capital	0	0	0	0	0	0	798,205	769,653	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	6,165	11,051	15,540	12,236	11,212	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	18	17	17	16	17	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	372,969	318,358	367,326	791,114	798,205	769,653	661,850	718,017	0	751,503	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	22,954	45	19,522	47,619	1,011,532	718,381	201,661	141,048	200,219	167,336	15,979	12,381	7,041	3,346	16,032	28,753	76,812	158,401	92,310	92,310	59,030	42,423	20,741	9,224	29,900	32,800	62,300	34,800	16,000	7,600
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	170,309	211,870	341,108	411,186	1,069,867	764,572	201,661	141,048	200,219	167,336	15,979	12,381	17,041	22,697	53,232	80,671	94,408	171,848	112,492	0	99,034	64,248	37,688	23,663	47,200	32,800	62,300	34,800	16,000	7,600
Common Stock	18	0	17	16	17	21	21	21	20	20	21	21	21	21	123	119	101	100	73	73	73	72	60	57	100	0	0	0	0	0
Common Stock Shares Outstanding	17,757	16,868	17,246	16,185	19,757	24,067	23,481	20,831	21,228	21,433	20,745	19,853	19,713	19,613	18,863	15,918	16,354	13,436	12,282	12,282	11,781	11,520	9,902	9,278	7,858	6,732	5,521	4,797	3,735	2,877
Common Stock Total Equity	0	0	17	16	17	21	21	21	20	20	21	21	21	21	123	119	101	100	73	73	73	72	60	57	100	0	0	0	0	0
Current Deferred Revenue	1,222	355	10,996	29,435	2,139	3,286	173	0	-934	150	116	486	1,240	1,702	6,691	12,265	1,964	59,945	152,528	0	2,564	4,683	8,729	0	0	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	123,891	189,083	0	0	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	59,095	64,598	32,937	0	3,525	0	0	3,183	0	3,094	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	103,370	448,128	734,996	784,992	305,677	306,439	314,543	276,912	60,585	62,961	65,337	68,150	14,894	700	700	5,375	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	366,897	10,182	10,110	10,979	20,090	31,460	19,526	25,821	8,554	4,568	4,571	55,912	57,437	12,951	2,515	5,375	0	83,083	127,443	127,443	137,857	148,546	41,879	44,924	0	0	0	0	0	0
Inventory	23,969	13,294	27,326	26,487	7,296	7,124	4,373	1,923	1,633	269	1,392	1,697	1,301	-22,697	-53,232	1,147	-10,467	3,856	11,772	11,772	8,262	4,841	3,756	5,651	5,700	6,200	0	0	0	0
Liabilities And Stockholders Equity	833,064	762,668	1,301,383	1,362,285	1,469,307	1,260,803	671,021	601,585	533,929	258,029	104,713	104,260	122,350	75,559	113,699	171,448	173,278	326,053	332,466	332,466	301,255	270,609	117,473	113,422	134,600	156,000	107,400	102,100	93,600	46,700
Long Term Debt	0	0	320,717	442,293	638,959	609,864	18,859	29,563	39,628	3,071	0	19,406	20,286	0	0	2,178	627	2,156	170,175	171,092	170,052	159,345	136,758	131,705	0	0	0	0	0	0
Long Term Debt Total	0	0	320,717	442,293	638,959	609,864	18,859	29,563	39,628	3,071	0	19,406	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	48,321	3,000	0	0	0	0	6,438	8,345	29,728	7,417	0	8,207	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	-16,789	87,701	316,735	406,910	-362,603	-82,084	22,868	71,862	5,153	28,906	-6,870	15,897	44,697	27,539	24,834	-24,746	-74,657	-118,495	81,706	77,703	113,501	114,914	121,384	125,959	110,900	60,900	-8,100	21,800	36,300	6,000
Net Invested Capital	700,913	674,180	1,142,346	1,151,818	1,406,191	1,197,211	643,176	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	39,312	35,038	91,646	59,064	41,748	55,850	29,473	17,907	10,952	12,956	6,551	8,916	6,110	993	9,782	12,100	10,467	11,521	30,847	30,847	19,051	7,356	9,798	12,824	1,700	0	0	3,100	2,300	1,200
Net Tangible Assets	0	139,175	76,523	-86,446	441,465	223,015	84,578	68,120	207,771	-20,295	0	-41,665	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	220,647	164,791	423,086	400,448	1,106,643	788,291	-1,847	-64,076	194,736	162,379	-4,058	-11,616	-11,413	1,389	15,994	23,315	58,975	64,747	-43,888	-43,888	76,108	53,218	21,848	16,234	36,000	51,100	62,400	71,600	57,300	33,500
Non Current Assets Total	595,635	499,067	836,632	861,726	345,662	390,263	434,000	438,532	318,357	72,871	79,832	80,437	90,120	38,540	45,533	77,519	63,335	90,496	159,642	0	171,098	186,856	63,899	68,773	77,900	78,000	23,300	16,700	20,600	5,100
Non Current Liabilities Other	2,961	25,422	39,459	45,758	38,785	7,776	9,981	3,603	3,330	19,907	0	19,836	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	113,925	66,373	438,089	552,649	685,073	617,640	13,506	3,603	208,702	210,842	26,161	42,336	70,061	46,920	57,783	111,199	93,195	127,891	191,071	0	176,478	166,059	143,622	140,132	139,500	140,500	51,400	53,800	49,800	12,300
Non Currrent Assets Other	21,530	14,218	23,252	18,701	9,542	-600,746	4,859	1,744	2,554	4,856	1,640	3,292	15,756	23,317	7,966	59,241	60,470	1,862	8,552	8,552	9,740	159,130	54,209	57,801	57,400	54,300	8,400	5,000	8,300	1,200
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	13,266	58,777	62,300	27,965	46,992	89,281	125,635	189,110	4,856	1,640	3,292	2,079	2,179	31,611	11,717	11,481	1,862	12,399	6,174	9,740	27,373	9,882	9,499	0	0	0	0	0	0
Other Current Assets	3,839	3,399	4,671	3,822	4,734	20,418	1,514	2,175	2,768	4,597	959	829	24,819	36,026	58,384	11	15,535	9,518	17,713	17,713	3,810	7,308	2,332	2,511	2,100	39,000	21,800	47,500	54,700	32,800
Other Current Liab	256	21,040	22,220	60,299	11,201	29,147	4,530	5,088	10,414	172	4,213	3,841	15,141	17,297	18,663	41,893	34,794	60,856	43,908	196,436	30,315	11,786	12,245	21,110	11,200	11,300	8,200	7,100	9,400	4,500
Other Liab	0	56,032	101,878	104,713	61,752	7,776	13,506	3,603	3,330	12,142	25,063	28,168	38,909	38,204	77,547	96,676	80,223	113,390	7,307	7,634	6,426	6,714	6,864	8,427	0	0	0	0	0	0
Other Stockholder Equity	198,696	597,035	373,439	318,358	367,326	791,114	817,064	799,216	701,478	680,660	718,017	714,104	690,396	687,046	684,682	669,061	610,517	890,535	719,041	0	726,499	692,302	557,326	513,832	467,900	402,000	326,500	223,100	175,500	106,800
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	18,859	29,563	39,628	0	0	0	8,344	8,344	8,344	12,345	12,345	12,345	12,345	12,345	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	31,717	15,009	32,749	21,326	17,538	5,372	4,212	1,819	372	486	867	788	455	559	8,522	12,903	2,865	5,551	23,647	23,647	23,501	9,672	9,690	10,972	20,500	23,700	14,900	11,700	12,300	3,900
Property Plant And Equipment Net	9,455	15,009	32,749	22,734	10,353	5,372	4,212	1,819	372	486	867	788	455	559	8,522	12,903	2,865	5,551	23,647	0	23,501	9,672	9,690	10,972	20,500	23,700	14,900	11,700	12,300	3,900
Property Plant Equipment	0	27,491	32,749	14,434	7,185	5,372	4,212	1,819	372	867	867	788	455	559	8,522	12,903	2,865	5,551	22,483	23,647	23,501	9,672	9,690	10,972	0	0	0	0	0	0
Retained Earnings	503,016	451	449,090	391,952	400,105	-229,197	-400,924	-431,127	-402,010	-659,315	-671,339	-682,759	-681,771	-691,947	-681,574	-679,626	-581,512	-862,802	-794,660	-794,660	-655,778	-618,316	-585,720	-542,725	-470,300	-395,600	-277,700	-177,600	-140,300	-76,100
Retained Earnings Total Equity	0	0	449,090	391,952	400,105	-229,197	-400,924	-431,127	-429,491	-671,339	0	-682,759	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	0	76,695	0	0	0	26,433	224,529	212,910	201,985	195,908	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	6,165	87,746	336,257	454,529	648,929	636,297	224,529	212,910	205,372	196,242	9,109	28,278	51,738	30,885	40,866	4,007	2,155	39,906	174,016	170,013	172,531	157,337	142,125	135,183	140,800	93,700	54,200	56,600	52,300	13,600
Short Term Debt	410	77,410	46	6,593	1,242	26,433	224,529	212,910	934	334	9,109	14,835	16,197	8,034	9,873	1,829	1,528	37,750	2,924	2,924	2,479	2,087	5,367	3,478	4,100	3,200	2,800	2,600	2,400	1,300
Short Term Investments	147,355	167	321,586	363,567	58,335	46,191	181,041	122,296	102,791	7,133	4,340	2,767	10,000	19,351	37,200	51,918	17,596	13,447	20,182	20,182	40,004	21,825	16,947	14,439	17,300	0	0	0	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	833,064	762,668	1,301,383	1,362,285	1,469,307	1,260,803	671,021	601,585	533,929	258,029	104,713	104,260	122,350	75,559	113,699	171,448	173,278	326,053	332,466	332,466	301,255	270,609	117,473	113,422	134,600	156,000	107,400	102,100	93,600	46,700
Total Current Assets	237,429	263,601	464,751	500,559	1,123,645	870,540	237,021	163,053	215,572	185,158	24,881	23,823	32,230	37,019	68,166	93,929	109,943	235,557	172,824	172,824	130,157	83,753	53,574	44,649	56,700	78,000	84,100	85,400	73,000	41,600
Total Current Liabilities	16,782	98,810	41,665	100,111	17,002	82,249	238,868	227,129	20,836	22,779	28,939	35,439	43,643	35,630	52,172	70,614	50,968	170,810	216,712	216,712	54,049	30,535	31,726	28,415	20,700	26,900	21,700	13,800	15,700	8,100
Total Liab	130,707	165,183	479,754	652,760	702,075	699,889	252,374	230,732	229,538	233,621	55,100	77,775	113,704	82,550	109,955	181,813	144,163	298,701	407,783	407,783	230,527	196,594	175,348	168,547	160,200	167,400	73,100	67,600	65,500	20,400
Total Permanent Equity	0	0	0	0	0	0	399,788	341,290	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	700,913	597,485	821,629	709,525	767,232	560,914	418,647	370,853	304,391	26,318	49,613	26,485	8,646	-6,991	3,744	-10,365	29,115	27,352	-75,317	0	70,728	74,015	-57,875	-55,125	-25,600	-11,400	34,300	34,500	28,100	26,300
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	-42,280	-42,280	-42,225	-42,134	-42,134	-40,521	-911	-911	-911	-911	-911	-911	-911	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	18,859	29,563	39,628	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31
Accounts Payable	14,894	13,110	16,873	6,135	5	16	33,704	22,849	8,403	7,233	17,273	9,469	3,784	24,667	18,931	3,365	2,420	15,100	14,428	19,832	23,383	1,647	13,694	3,407	9,636	3,617	7,124	6,456	9,131	10,937	2,336	6,955	10,422	3,143	17,949	7,442	22,123	17,573	15,532	3,675	15,501	15,579	4,755	5,522	16,277	6,027	6,746	7,893	11,065	10,072	10,628	13,032	8,597	11,339	13,445	14,519	16,945	14,379	14,844	15,641	14,627	9,014	10,290	10,760	12,682	10,448	10,939	13,181	12,259	16,080	19,460	16,325	15,360	17,352	14,276	14,586	17,352	16,719	20,225	16,866	18,691	17,261	10,819	13,441	11,979	9,662	10,026	7,033	5,385	4,418	4,111	3,890	3,827	4,455	5,065	4,822	5,400	5,500	7,600	7,100	12,400	5,500	7,300	4,100	10,700	3,600	3,200	3,500	4,100	1,700	2,400	1,700	3,900	2,100	-	1,000	2,300	1,200	1,300	1,000
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Accumulated Other Comprehensive Income	-817	-944	-967	-935	-1	-1	-1,066	-1,031	-917	-875	-861	-856	-801	-1,441	-2,310	-4,867	-216	-1,493	-542	-503	-1,024	-64	-151	-286	2,486	3,335	3,059	3,105	2,743	3,652	3,745	3,568	4,903	5,558	11,265	9,334	4,953	3,543	5,041	10,943	2,914	2,201	1,395	1,166	-4,881	-4,800	-4,882	-4,859	-4,771	-9,500	-9,389	5	31	76	885	1,021	513	317	94	11	81	103	-28	-43	9	-110	-155	-140	-481	-138	30	1,021	490	229	-41,097	-1,000	-41,097	-123	-127	-53	-66	-88	-46	-61	-43	-60	-72	-395	-678	-974	-1,322	-1,649	-2,030	-2,358	-2,771	-3,162	-4,100	-2,600	-20,500	-19,100	-17,800	-17,700	-16,600	-15,500	-14,500	-13,900	-11,000	-11,000	-11,000	-9,000	-9,000	-8,100	-7,100	-4,400	-	-4,400	-4,400	0	0	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	798,205	0	0	0	769,653	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Capital Lease Obligations	6,165	6,329	11,671	11,886	11,051	37,286	2,551	1,902	15,540	13,693	2,320	7,610	12,236	4,949	10,909	10,714	11,212	10,858	11,478	1,187	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Capital Stock	18	18	17	17	17	17	17	17	17	17	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Capital Surpluse	0	0	170,741	154,424	0	348,994	335,471	325,368	372,969	358,418	346,578	336,621	318,358	313,057	304,404	295,940	367,326	444,587	619,255	643,317	791,114	883,477	874,183	808,765	798,205	793,724	784,376	777,102	769,653	762,576	755,049	783,890	661,850	697,061	692,765	684,355	718,017	707,180	726,758	723,279	0	758,080	755,305	752,952	751,503	0	0	741,889	732,676	731,899	730,966	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Cash	22,954	19,275	219,041	282,665	45	121	5,280	14,993	19,522	23,430	21,863	31,853	47,619	456,916	809,880	738,811	1,011,532	1,099,685	1,332,049	1,428,688	718,381	115,560	956,927	51,024	201,661	32,739	172,627	10,641	141,048	124,115	61,350	113,201	200,219	93,770	181,609	165,766	167,336	186,588	22,027	12,977	15,979	3,271	5,923	5,037	12,381	7,046	8,885	9,777	7,041	2,251	3,441	6,033	3,346	3,796	3,235	4,044	16,032	5,160	3,549	4,920	28,753	11,801	29,177	59,543	76,812	69,301	103,611	403,911	158,401	10,029	41,615	49,808	66,756	92,310	32,580	50,956	92,310	46,020	41,920	65,558	59,030	73,002	24,248	12,979	42,423	23,177	25,087	18,191	20,741	17,755	28,600	20,972	9,224	11,969	23,157	23,877	29,900	26,700	8,400	11,000	32,800	24,900	25,600	26,100	62,300	13,400	17,700	22,800	34,800	7,000	11,200	16,500	16,000	12,200	-	13,300	7,600	12,100	700	2,100
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Cash And Short Term Investments	170,309	190,502	219,041	282,665	211,870	239	147,935	203,999	341,108	323,211	301,835	339,207	411,186	795,070	809,880	771,690	1,069,867	1,149,541	1,392,425	1,501,429	764,572	1,111,871	1,016,723	291,888	201,661	202,259	172,627	159,374	141,048	124,115	106,953	113,201	200,219	187,298	181,609	177,225	167,336	186,588	22,027	25,252	15,979	3,271	5,923	5,037	12,381	7,046	10,385	11,294	17,041	12,251	13,441	16,520	22,697	24,069	32,195	39,056	53,232	44,193	55,510	52,604	80,671	71,112	84,996	90,228	94,408	98,392	115,400	410,230	171,848	31,891	60,783	67,705	86,930	112,492	0	0	0	80,407	85,878	97,183	99,034	86,746	41,843	33,983	64,248	35,276	42,556	37,622	37,688	39,424	45,559	40,885	23,663	31,562	46,492	47,682	47,200	45,800	33,700	46,700	32,800	24,900	25,600	26,100	62,300	13,400	17,700	22,800	34,800	7,000	11,200	16,500	16,000	12,200	-	13,300	7,600	12,100	700	2,100
Common Stock	18	18	17	17	0	0	17	17	17	17	17	17	16	16	16	16	17	17	19	20	21	21	21	21	21	21	21	21	21	28	21	21	20	20	20	20	20	20	21	21	21	22	21	21	21	21	21	21	21	21	21	21	21	21	124	123	123	119	119	119	119	101	101	101	101	100	101	100	100	78	78	78	73	73	73	73	73	74	74	74	73	73	70	70	72	71	71	67	60	60	60	59	57	56	56	55	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Common Stock Shares Outstanding	17,676	17,380	17,730	17,974	16,890	17,132	16,868	16,824	16,733	17,142	17,172	17,248	16,684	16,082	16,694	16,529	17,243	18,770	19,558	21,277	21,071	24,052	24,438	24,800	21,109	23,551	23,216	23,019	20,898	22,997	20,832	22,284	21,542	21,460	21,276	20,631	20,792	21,345	21,780	21,208	21,056	20,844	20,427	20,280	20,124	19,918	19,749	19,709	19,713	19,673	19,650	19,623	19,613	19,630	19,609	19,576	18,863	18,857	18,858	18,853	15,918	15,845	15,843	15,841	16,354	16,090	16,646	16,781	13,436	13,112	13,090	12,916	12,337	12,282	12,339	12,319	12,319	12,308	12,292	12,217	11,781	11,683	11,546	11,706	11,520	11,893	11,736	10,521	9,902	9,930	9,897	9,809	9,278	9,434	9,267	8,967	7,858	7,913	7,839	7,632	6,732	6,722	6,444	6,428	5,521	5,524	5,417	5,260	4,797	4,667	4,630	4,733	3,735	4,427	3,699	3,118	2,877	2,500	2,418	2,396
Common Stock Total Equity	0	0	17	17	0	17	17	17	17	17	17	17	16	16	16	16	17	17	19	20	21	21	21	21	21	21	21	21	21	28	21	21	20	20	20	20	20	20	21	21	21	22	21	21	21	21	21	21	21	21	21	21	21	21	124	123	123	119	119	119	119	101	101	101	101	100	101	100	100	78	78	78	73	73	73	73	73	74	74	74	73	73	70	70	72	71	71	67	60	60	60	59	57	56	56	55	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Current Deferred Revenue	1,222	4,343	11,387	257	355	10	10,584	10,503	10,996	12,007	17,147	25,107	29,435	5,404	11,023	4,354	2,139	2,230	939	2,808	3,286	2,450	1,700	75	173	1,075	0	4,680	123,891	-1,505	4,951	-577	216,564	2,083	2,083	67	150	114	92	2,085	116	336	452	556	486	458	412	727	1,240	426	889	1,304	1,702	1,702	2,663	6,025	6,691	12,626	12,223	12,156	12,265	2,546	1,964	1,964	1,964	1,964	1,964	1,964	59,945	80,395	143,102	151,021	157,519	152,528	0	0	0	2,352	2,381	2,346	2,564	3,502	4,126	4,637	4,683	3,319	10,302	7,415	8,729	10,043	0	8,541	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	138,837	141,007	123,891	133,486	133,595	129,777	189,083	206,423	0	0	0	0	0	0	0	0	0	0	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Deferred Long Term Liab	0	0	27,665	30,010	0	29,832	42,669	39,480	59,095	63,026	60,053	56,812	64,598	13,508	23,340	21,769	32,937	3,761	694	9,614	0	0	0	3,000	3,525	0	0	0	0	0	0	0	0	2,083	5,142	4,882	3,183	3,299	3,189	3,236	0	3,047	2,986	2,916	3,094	0	0	5,742	0	4,475	4,428	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Good Will	103,370	418,613	431,050	439,589	448,128	181	709,570	720,913	734,996	190,183	762,523	774,300	784,992	326,718	318,664	300,861	305,677	309,781	300,609	303,099	306,439	85,961	307,962	85,961	314,543	72,207	271,491	72,207	276,912	279,794	72,360	285,820	60,585	12,238	61,773	12,238	62,961	63,555	64,149	12,238	65,337	65,930	12,238	12,238	68,150	12,238	14,894	14,894	14,894	14,251	14,250	15,213	700	700	700	700	700	0	0	347	5,375	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Intangible Assets	366,897	6,602	10,783	10,431	10,182	517	10,267	10,121	10,110	573,120	10,638	10,451	10,979	10,834	10,606	10,381	20,090	35,413	40,008	31,023	31,460	237,210	20,437	245,275	19,526	220,299	22,962	227,620	25,821	233,420	236,283	8,546	8,554	57,539	8,598	54,697	4,568	4,568	4,567	57,076	4,571	4,571	58,816	55,319	55,912	56,580	56,273	56,855	57,437	57,986	60,907	61,544	12,951	15,833	15,833	13,758	2,515	482	1,659	1,838	5,375	0	0	0	0	0	0	83,083	83,083	84,990	139,766	143,268	146,770	127,443	153,773	144,275	127,443	129,852	132,520	135,189	137,857	140,526	143,194	145,862	148,546	44,396	36,358	37,118	41,879	38,641	0	40,163	44,924	0	0	0	0	39,300	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Inventory	23,969	25,392	26,906	14,011	13,294	22	24,773	25,614	27,326	32,996	39,946	36,932	26,487	13,430	3,702	7,320	7,296	6,565	9,638	11,905	7,124	8,136	9,520	10,531	4,373	5,007	6,809	7,629	1,923	4,027	3,835	1,750	1,633	1,221	802	2,821	269	1,071	817	1,949	1,392	1,838	2,265	2,838	1,697	2,548	2,698	1,345	1,301	1,960	2,594	4,212	0	0	0	0	3,170	-44,193	-55,510	0	1,147	1,427	-8,682	1,252	0	1,914	1,683	1,980	3,856	5,039	8,467	8,232	9,333	11,772	6,328	6,896	11,772	11,355	11,752	9,770	8,262	6,005	4,806	5,395	4,841	3,155	2,305	2,828	3,756	4,471	4,519	5,022	5,651	6,245	5,456	5,908	5,700	5,800	6,500	6,200	6,200	1,500	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Liabilities And Stockholders Equity	833,064	769,210	758,105	811,076	762,668	1,051	1,076,288	1,105,184	1,301,383	1,273,656	1,256,283	1,295,121	1,362,285	1,247,449	1,242,936	1,185,917	1,469,307	1,547,476	1,801,836	1,913,988	1,260,803	2,105,742	1,858,284	754,668	671,021	662,337	640,024	629,723	601,585	600,865	616,799	613,438	533,929	521,700	304,762	263,223	258,029	272,283	99,847	105,471	104,713	101,677	99,571	98,363	104,260	97,506	104,594	111,798	122,350	122,466	127,435	134,153	75,559	112,568	127,597	133,620	141,807	117,086	129,176	139,587	171,448	147,191	160,023	166,265	173,278	211,524	228,476	524,810	326,053	231,867	285,932	288,689	314,619	332,466	301,723	313,253	332,466	288,659	285,317	294,189	301,255	272,797	226,932	241,176	270,609	118,026	127,657	118,906	117,473	116,962	124,700	126,220	113,422	115,011	128,992	129,558	134,600	131,700	123,300	135,300	156,000	125,700	82,300	89,500	107,400	77,900	87,800	96,000	102,100	67,600	76,700	85,600	93,600	93,200	-	45,200	46,700	52,100	36,000	43,200
Long Term Debt	0	0	0	0	0	0	0	176,540	320,717	316,889	315,318	352,313	442,293	454,973	449,672	444,432	638,959	631,533	624,209	616,987	609,864	602,839	595,912	0	0	0	0	0	0	0	0	204,653	0	202,951	200,567	198,796	3,071	194,764	1,587	2,339	0	3,725	6,275	10,568	19,406	17,876	22,211	34,151	20,286	29,371	29,975	20,029	0	0	0	0	0	0	25	54	2,178	172	266	403	627	889	1,259	1,641	2,156	142,070	142,314	143,804	170,175	170,195	170,829	171,115	171,092	171,258	170,803	170,846	170,052	157,932	158,653	158,957	159,345	3,732	2,640	6,869	136,758	137,061	135,157	133,344	131,705	120,196	118,721	117,109	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Long Term Debt Total	0	0	0	0	0	0	0	176,540	320,717	316,889	315,318	352,313	442,293	454,973	449,672	444,432	638,959	631,533	624,209	616,987	609,864	602,839	595,912	0	0	0	0	0	0	0	0	204,653	0	202,951	200,795	198,796	3,071	194,764	1,587	2,339	0	3,725	6,275	10,568	19,406	0	0	34,151	0	29,371	29,975	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Long Term Investments	48,321	47,163	0	0	3,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6,438	5,137	6,014	10,469	8,345	17,339	18,733	28,118	29,728	31,826	33,996	0	7,417	0	413	448	0	8,387	8,579	7,916	8,207	0	0	14,226	0	20,616	21,346	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Net Debt	-16,789	-12,946	-207,370	-193,989	87,701	-42	139,333	163,449	316,735	307,152	295,775	328,070	406,910	-1,943	-360,208	-294,379	-362,603	-468,152	-680,753	-784,945	-82,084	700,423	-150,645	176,523	22,868	188,818	46,003	205,107	71,862	86,000	146,013	91,452	5,153	109,181	18,958	32,801	28,906	7,380	-19,329	-7,208	-6,870	9,104	9,647	13,669	15,897	30,623	20,632	19,594	23,245	65,766	36,534	34,844	19,505	39,894	45,753	34,871	20,333	52,311	54,381	53,486	-24,746	-10,913	-27,933	-57,902	-74,657	-66,602	-100,363	-400,119	-118,495	132,404	103,201	96,644	106,164	81,706	137,308	119,022	77,703	128,169	128,092	108,030	113,501	82,248	140,421	144,376	114,914	-7,218	-17,355	37,819	121,384	121,857	125,807	115,360	125,959	112,127	99,813	97,454	110,900	131,600	87,900	83,400	60,900	27,900	26,100	28,700	-8,100	39,200	36,700	30,800	21,800	43,800	42,700	36,800	36,300	38,700	-	0	6,000	1,400	2,800	1,400
Net Invested Capital	700,913	665,402	664,892	723,107	674,180	892,898	917,339	969,732	1,142,346	1,128,955	1,101,835	1,098,153	1,151,818	1,152,797	1,144,675	1,106,328	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Net Receivables	39,312	39,187	27,994	29,188	35,038	66	63,272	41,797	91,646	70,714	62,850	55,581	59,064	32,907	44,553	46,777	41,748	21,958	20,259	26,615	55,850	46,976	42,001	40,985	29,473	15,823	16,669	7,057	17,907	9,793	13,653	16,546	10,952	11,347	11,079	7,541	12,956	6,335	3,524	5,681	6,551	10,014	5,534	8,879	8,916	6,588	817	1,992	12,307	9,749	9,067	9,413	13,602	9,876	9,777	10,014	10,400	2,110	1,050	13,912	12,100	2,128	8,682	10,416	0	15,377	15,017	15,659	11,521	7,077	18,667	20,046	20,954	30,847	21,016	18,324	30,847	30,583	17,936	14,185	19,051	9,923	7,689	17,086	7,356	7,001	13,498	7,569	9,798	6,434	5,163	4,911	12,824	3,049	1,938	2,461	1,700	2,300	2,900	4,300	0	0	0	0	0	3,100	3,000	2,300	3,100	2,700	2,000	1,900	2,300	1,300	-	700	1,200	800	700	700
Net Tangible Assets	0	0	654,109	635,886	139,175	806,105	792,098	783,071	76,523	801,318	13,356	735,389	-86,446	360,272	365,733	350,654	441,465	505,387	700,836	745,852	223,015	376,349	291,414	165,942	84,578	132,257	114,956	98,951	68,120	64,614	55,792	70,230	207,771	222,404	-1,318	-31,787	-20,295	-23,751	-4,546	-4,313	0	-25,686	-31,786	-36,961	-41,665	0	0	-51,451	16,529	11,403	14,213	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Net Working Capital	220,647	238,895	247,323	229,266	164,791	85,191	75,931	233,488	423,086	395,785	358,404	341,623	400,448	815,441	834,360	810,289	1,106,643	1,147,408	1,333,322	1,381,118	788,291	951,881	847,620	102,072	-1,847	-7,482	-28,663	-52,294	-64,076	-85,440	-93,784	120,819	194,736	194,071	178,776	173,556	162,379	180,087	9,964	12,398	-4,058	-15,826	-18,001	-15,277	-11,616	-12,445	-9,323	-3,662	-11,413	-15,637	-14,176	-13,274	3,531	-1,393	-196	8,953	15,994	6,848	21,268	14,811	23,315	34,264	51,500	57,588	58,975	55,943	64,125	87,446	64,747	-161,888	-154,509	-143,689	-102,244	-43,888	-104,939	-84,515	-43,888	53,801	57,341	67,644	76,108	59,572	21,819	25,188	53,218	20,657	29,538	-27,165	21,848	27,001	32,126	34,764	16,234	21,581	31,129	36,020	36,000	35,500	23,400	38,300	51,100	27,300	32,600	49,300	62,400	42,600	51,300	62,900	71,600	39,800	46,900	55,000	57,300	-	-	32,800	33,500	39,700	26,200	33,500
Non Current Assets Total	595,635	511,449	481,394	482,881	499,067	830	832,504	829,118	836,632	841,574	845,382	857,693	861,726	389,708	379,312	355,190	345,662	364,373	359,529	346,093	390,263	360,517	377,814	405,617	434,000	438,136	442,847	455,022	438,532	460,174	490,236	480,379	318,357	311,376	108,037	71,510	72,871	73,763	71,262	72,068	79,832	85,042	85,001	80,623	80,437	80,072	83,498	88,254	90,120	95,649	99,296	102,857	38,540	77,281	84,195	83,233	73,641	57,191	59,706	71,892	77,519	61,226	63,911	64,366	63,335	95,749	96,293	96,863	90,496	167,340	172,029	176,349	181,652	159,642	0	0	0	163,329	166,506	169,287	171,098	166,935	169,959	178,165	186,856	69,759	66,438	67,756	63,899	64,929	67,119	68,609	68,773	70,975	73,483	71,147	77,900	77,000	79,100	77,000	78,000	79,700	30,000	25,700	23,300	23,100	23,400	20,100	16,700	16,700	17,200	17,800	20,600	19,200	-	5,300	5,100	5,300	4,700	4,600
Non Current Liabilities Other	2,961	47,185	25,169	24,637	25,422	69,234	63,401	53,394	39,459	45,378	41,898	44,351	45,758	38,844	45,657	37,382	38,785	25,906	26,495	20,636	7,776	10,039	9,709	7,511	9,981	5,891	4,775	3,950	3,603	4,341	4,536	4,468	3,330	8,232	11,823	8,993	19,907	13,004	13,364	13,890	0	17,629	18,471	21,266	19,836	0	0	24,401	0	35,455	37,046	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Non Current Liabilities Total	113,925	84,942	63,825	65,830	66,373	106	106,070	269,414	438,089	425,293	417,269	453,476	552,649	507,325	516,563	503,583	685,073	661,200	651,398	647,237	617,640	612,878	605,621	10,511	13,506	5,891	4,775	3,950	3,603	4,341	4,536	209,121	208,702	213,266	217,760	212,671	210,842	211,067	18,140	19,465	26,161	24,401	27,732	34,750	42,336	46,392	55,723	65,349	70,061	77,645	79,793	84,574	46,920	85,328	81,343	90,041	85,891	73,536	93,233	101,401	111,199	93,536	96,390	97,420	93,195	125,402	126,186	114,562	127,891	256,642	256,022	257,018	189,827	191,071	0	0	0	176,171	175,848	176,560	176,478	163,911	164,721	165,330	166,059	9,751	8,964	9,569	143,622	144,104	144,873	141,601	140,132	122,896	121,421	119,809	139,500	157,500	132,800	131,100	140,500	99,700	48,900	52,200	51,400	49,600	51,600	50,800	53,800	48,000	51,400	50,600	49,800	49,600	-	12,000	12,300	12,300	2,400	2,200
Non Currrent Assets Other	21,530	20,740	15,877	16,377	14,218	50	37,270	31,026	23,252	3,095	20,456	19,949	18,701	25,130	23,631	17,590	9,542	19,179	18,912	11,971	5,843	499	4,829	894	4,859	2,028	1,668	5,028	1,744	1,744	603	70	2,554	2,995	206	958	4,856	5,089	1,514	1,616	9,057	5,320	4,556	4,384	3,292	1,757	10,109	16,130	17,334	20,199	2,114	2,224	25,030	34,071	34,880	6,878	6,543	46,816	47,588	10,365	59,241	59,539	61,887	62,275	60,470	92,315	92,510	92,841	1,862	60,897	10,702	11,323	12,399	8,552	16,481	14,002	8,552	9,633	10,076	10,478	9,740	17,337	17,922	23,074	177,184	59,607	19,842	20,247	54,209	16,540	56,680	17,547	57,801	59,191	60,857	58,102	57,400	16,000	56,600	54,100	54,300	49,300	14,500	10,200	8,400	8,100	8,400	8,400	5,000	4,900	5,300	5,200	8,300	7,900	-	1,500	1,200	1,600	1,000	900
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2,753	-1,910	-1,589	-1,084	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Other Assets	0	0	13,025	0	13,266	41,779	41,970	42,097	58,777	29,823	48,338	47,381	62,300	40,730	32,470	27,628	27,965	2,488	1,680	1,515	46,992	32,939	45,228	70,262	429,788	434,610	440,972	453,124	436,713	458,348	461,574	452,331	287,977	311,021	107,632	71,070	72,385	73,212	70,643	71,378	78,965	84,208	84,197	79,865	79,649	79,219	81,087	86,112	89,665	95,663	99,159	102,604	37,981	76,313	77,122	75,461	65,119	47,298	49,247	60,697	64,616	59,539	61,887	62,275	60,470	92,315	92,510	92,841	84,945	145,887	150,468	154,591	159,169	165,701	170,254	158,277	135,995	139,485	142,596	145,667	147,597	157,863	161,116	168,936	177,184	59,607	56,200	57,365	54,209	55,181	56,680	57,710	57,801	59,191	60,857	58,102	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Other Current Assets	3,839	2,680	2,770	2,331	3,399	-107	7,804	4,656	4,671	5,161	6,270	5,708	3,822	3,191	5,489	4,940	4,734	5,039	5,672	9,228	20,418	25,339	12,817	5,647	1,514	1,112	1,072	641	2,175	136,664	2,122	1,562	2,768	10,458	2,635	2,408	4,597	4,526	2,217	521	959	1,512	848	986	829	1,015	17,581	20,207	1,344	1,663	1,868	1,151	720	1,342	1,430	1,317	1,364	57,785	68,420	1,179	11	11,298	11,116	3	15,535	92	83	78	9,518	20,520	25,986	16,357	15,750	17,713	12,924	17,076	17,713	2,985	3,245	3,764	3,810	3,188	2,635	6,547	7,308	2,835	2,860	3,131	2,332	1,704	2,340	6,793	2,511	3,180	1,623	2,360	2,100	800	1,100	1,100	39,000	19,600	26,700	37,700	21,800	38,300	43,700	50,800	47,500	41,200	46,300	49,400	54,700	60,500	-	25,900	32,800	33,900	29,900	35,800
Other Current Liab	256	916	448	15,044	21,040	98	6,040	7,324	22,220	14,831	15,757	53,619	60,299	11,200	-312	11,236	11,201	17,439	66,531	137,381	29,147	576,103	407,086	15,950	4,530	5,434	86	111	-118,803	6,584	5,697	5,285	-207,084	9,727	-3,721	10,300	172	409	299	9,476	4,213	4,171	13,764	13,727	3,841	10,135	15,955	15,650	21,338	13,926	20,798	19,934	13,330	8,567	7,888	16,316	28,445	13,945	9,376	13,541	41,893	39,425	31,380	30,349	34,794	45,610	53,166	323,205	60,856	129,577	103,348	86,035	59,587	43,908	196,236	198,654	196,436	49,527	36,108	35,304	30,315	2,299	14,193	17,640	11,786	5,721	6,261	10,736	12,245	8,020	9,110	7,428	21,110	14,100	15,066	13,347	11,200	10,000	9,700	9,600	11,300	10,100	9,600	7,700	8,200	5,700	7,000	6,700	7,100	6,700	7,600	8,400	9,400	7,500	-	4,800	4,500	4,700	2,600	2,900
Other Liab	0	0	52,834	0	56,032	64,159	78,955	76,077	101,878	96,937	101,951	101,163	104,713	48,432	59,816	49,920	61,752	19,735	16,700	25,930	7,776	10,039	9,709	10,511	13,506	5,891	4,775	3,950	3,603	4,341	4,536	4,468	3,330	10,315	14,134	11,655	12,142	16,222	17,036	18,314	25,063	23,439	24,861	28,465	28,168	25,854	29,798	35,487	38,909	45,917	48,198	53,337	38,204	76,984	72,999	81,697	77,547	65,192	84,864	89,002	96,676	81,019	83,779	84,672	80,223	112,168	112,582	112,921	113,390	102,227	101,363	100,869	7,307	7,326	7,458	7,533	7,634	4,913	5,045	5,714	6,426	5,979	6,068	6,373	6,714	6,019	6,324	2,700	6,864	7,043	9,716	8,257	8,427	2,700	2,700	2,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Other Stockholder Equity	198,696	181,500	170,741	154,424	597,035	349	335,471	325,368	822,096	358,418	346,578	336,621	318,358	313,057	304,404	295,940	367,326	444,587	619,255	643,317	791,114	883,477	874,183	824,843	817,064	815,321	808,669	804,050	799,216	794,714	789,315	783,890	701,478	697,061	692,765	684,355	680,660	707,180	726,758	723,279	718,017	715,800	713,025	710,672	714,104	709,836	701,085	699,609	690,396	689,619	688,686	687,443	687,046	686,914	686,255	685,331	684,682	674,651	673,915	669,887	669,061	611,749	610,822	609,921	610,517	613,750	622,984	646,321	890,535	753,036	750,636	747,831	720,077	719,041	0	0	0	730,930	731,185	729,267	726,499	724,333	677,666	676,650	692,302	721,723	721,023	652,791	557,326	546,720	545,522	542,308	513,832	511,720	508,198	495,907	467,900	405,100	419,400	413,500	402,000	380,000	339,000	329,600	326,500	239,700	232,200	230,900	223,100	183,300	179,100	177,700	175,500	169,000	-	112,400	106,800	102,300	91,800	91,900
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16,078	18,859	21,597	24,293	26,948	29,563	32,138	34,673	0	39,628	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8,344	8,344	8,344	8,344	8,344	8,344	8,344	8,344	8,344	8,344	8,344	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	12,345	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Property Plant And Equipment Gross	31,717	9,801	11,382	11,743	15,009	33,418	30,954	24,584	0	18,702	24,128	24,507	21,326	11,426	17,572	16,320	17,538	16,691	17,232	5,575	5,372	4,407	4,187	4,119	4,212	3,526	1,875	1,898	1,819	1,826	1,181	567	372	355	405	440	486	551	619	690	867	834	804	758	788	853	644	375	455	678	679	795	559	968	7,073	7,772	8,522	9,893	10,459	11,195	12,903	1,687	2,024	2,091	2,865	3,434	3,783	4,022	5,551	21,453	21,561	21,758	22,483	23,647	22,927	23,275	23,647	23,844	23,910	23,620	23,501	9,072	8,843	9,229	9,672	10,152	10,238	10,391	9,690	9,748	10,439	10,899	10,972	11,784	12,626	13,045	20,500	21,700	22,500	22,900	23,700	14,900	15,500	15,500	14,900	15,000	15,000	11,700	11,700	11,800	11,900	12,600	12,300	11,300	-	3,800	3,900	3,700	3,700	3,700
Property Plant And Equipment Net	9,455	9,801	15,154	15,609	15,009	47	39,743	31,403	32,749	48,448	23,883	25,561	22,734	11,426	17,572	16,320	10,353	16,691	17,232	5,575	5,372	4,407	4,187	4,119	4,212	3,526	1,875	1,898	1,819	1,826	1,181	567	372	355	405	440	486	551	619	690	867	834	804	758	788	853	644	375	455	678	679	795	559	968	7,073	7,772	8,522	9,893	10,459	11,195	12,903	1,687	2,024	2,091	2,865	3,434	3,783	4,022	5,551	21,453	21,561	21,758	22,483	23,647	0	0	0	23,844	23,910	23,620	23,501	9,072	8,843	9,229	9,672	10,152	10,238	10,391	9,690	9,748	10,439	10,899	10,972	11,784	12,626	13,045	20,500	21,700	22,500	22,900	23,700	30,400	15,500	15,500	14,900	15,000	15,000	11,700	11,700	11,800	11,900	12,600	12,300	11,300	-	3,800	3,900	3,700	3,700	3,700
Property Plant Equipment	0	0	11,382	11,743	27,491	33,418	30,954	24,584	32,749	18,702	23,883	16,896	14,434	7,157	7,883	6,690	7,185	6,411	6,268	5,575	5,372	4,407	4,187	4,119	4,212	3,526	1,875	1,898	1,819	1,826	1,181	567	372	355	405	440	867	551	619	690	867	834	804	758	788	853	644	375	455	678	679	795	559	968	7,073	7,772	8,522	9,893	10,459	11,195	12,903	1,687	2,024	2,091	2,865	3,434	3,783	4,022	5,551	21,453	21,561	21,758	22,483	22,638	22,927	23,275	23,647	23,844	23,910	23,620	23,501	9,072	8,843	9,229	9,672	10,152	10,238	10,391	9,690	9,748	10,439	10,899	10,972	11,784	12,626	13,045	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Retained Earnings	503,016	484,828	495,101	492,811	451	467,943	467,943	468,838	449,090	454,506	440,783	410,058	391,952	386,192	392,893	370,807	400,105	407,470	422,721	437,140	-229,197	-183,914	-254,240	-327,400	-400,924	-393,914	-402,340	-408,398	-431,127	-428,001	-401,165	-395,402	-402,010	-410,458	-634,997	-658,561	-659,315	-666,371	-667,650	-669,242	-671,339	-673,208	-675,173	-681,263	-682,759	-683,822	-682,654	-680,387	-681,771	-687,273	-683,380	-682,460	-691,947	-696,451	-684,608	-684,330	-681,574	-684,584	-686,387	-684,715	-679,626	-609,999	-591,874	-585,445	-581,512	-587,450	-588,698	-588,879	-862,802	-1,004,166	-989,246	-973,288	-831,059	-794,660	-822,056	-813,132	-794,660	-689,922	-683,133	-668,917	-655,778	-661,722	-650,633	-638,636	-618,316	-611,588	-604,541	-592,295	-585,720	-572,665	-564,921	-554,306	-542,725	-516,689	-501,763	-485,304	-470,300	-447,500	-429,200	-410,200	-395,600	-355,000	-308,700	-291,300	-277,700	-209,700	-198,100	-187,700	-177,600	-165,800	-157,400	-147,400	-140,300	-131,900	-	-81,900	-76,100	-69,600	-63,300	-56,000
Retained Earnings Total Equity	0	0	495,101	492,811	0	468,347	467,943	468,838	449,090	454,506	440,783	410,058	391,952	386,192	392,893	370,807	400,105	407,470	422,721	437,140	-229,197	-183,914	-254,240	-327,400	-400,924	-393,914	-402,340	-408,398	-431,127	-428,001	-429,053	-422,883	-429,491	-410,458	-634,997	-658,561	-671,339	-666,371	-667,650	-669,242	0	-673,208	-675,173	-681,263	-682,759	0	0	-681,099	-682,232	-686,581	-682,838	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Short Long Term Debt	0	0	0	76,790	76,695	76,600	114,974	0	0	0	0	0	0	0	0	0	0	0	27,087	26,756	26,433	213,144	210,370	227,547	224,529	221,557	218,630	215,748	212,910	210,115	207,363	207,363	201,985	0	0	0	195,908	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Short Long Term Debt Total	6,165	6,329	11,671	88,676	87,746	78,993	144,613	178,442	336,257	330,582	317,638	359,923	454,529	454,973	449,672	444,432	648,929	631,533	651,296	643,743	636,297	815,983	806,282	227,547	224,529	221,557	218,630	215,748	212,910	210,115	207,363	204,653	205,372	202,951	200,567	198,567	196,242	193,968	2,698	5,769	9,109	12,375	15,570	18,706	28,278	37,669	29,517	29,371	30,286	68,017	39,975	40,877	22,851	43,690	48,988	38,915	36,365	57,471	57,930	58,406	4,007	888	1,244	1,641	2,155	2,699	3,248	3,792	39,906	142,433	144,816	146,452	172,920	174,016	169,888	169,978	170,013	174,189	170,012	173,588	172,531	155,250	164,669	157,355	157,337	15,959	7,732	56,010	142,125	139,612	154,407	136,332	135,183	124,096	122,970	121,331	140,800	158,300	96,300	94,400	93,700	52,800	51,700	54,800	54,200	52,600	54,400	53,600	56,600	50,800	53,900	53,300	52,300	50,900	-	13,300	13,600	13,500	3,500	3,500
Short Term Debt	410	497	680	77,493	77,410	2,393	117,525	1,902	46	2,226	2,320	7,610	6,593	1,029	1,728	1,483	1,242	926	27,087	26,756	26,433	213,144	210,370	227,547	224,529	221,557	218,630	215,748	212,910	210,115	207,363	577	934	1,300	1,638	348	334	337	2,698	5,769	9,109	12,375	13,600	13,212	14,835	13,259	7,306	2,936	10,000	18,030	10,000	10,300	9,859	15,072	19,602	4,574	91	12,097	11,759	11,546	1,829	716	978	1,238	1,528	1,810	1,989	2,151	37,750	363	2,502	2,648	2,745	2,924	2,969	2,976	2,924	2,931	2,756	2,742	2,479	23,228	6,016	2,105	2,087	8,908	5,092	53,131	5,367	2,551	12,234	2,988	3,478	3,900	4,249	4,222	4,100	3,700	3,500	3,300	3,200	3,100	2,800	2,700	2,800	2,900	2,900	2,800	2,600	2,700	2,600	2,700	2,400	1,300	-	1,300	1,300	1,200	1,200	1,200
Short Term Investments	147,355	171,227	190,596	193,937	167	117	142,655	189,006	321,586	299,781	279,972	307,354	363,567	338,154	694,724	32,879	58,335	49,856	60,376	72,741	46,191	996,311	59,796	240,864	181,041	169,520	112,404	148,733	122,296	37,535	45,603	81,908	102,791	93,528	73,371	11,459	7,133	5,925	7,490	12,275	4,340	4,968	4,162	3,933	2,767	1,341	1,500	1,517	10,000	10,000	10,000	10,487	19,351	20,273	28,960	35,012	37,200	39,033	51,961	47,684	51,918	59,311	55,819	30,685	17,596	29,091	11,789	6,319	13,447	21,862	19,168	17,897	20,174	20,182	35,694	38,449	20,182	34,387	43,958	31,625	40,004	13,744	17,595	21,004	21,825	12,099	17,469	19,431	16,947	21,669	16,959	19,913	14,439	19,593	23,335	23,805	17,300	19,100	25,300	35,700	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Total Assets	833,064	769,210	758,105	811,076	762,668	1,051	1,076,288	1,105,184	1,301,383	1,273,656	1,256,283	1,295,121	1,362,285	1,247,449	1,242,936	1,185,917	1,469,307	1,547,476	1,801,836	1,913,988	1,260,803	2,105,742	1,858,284	754,668	671,021	662,337	640,024	629,723	601,585	600,865	616,799	613,438	533,929	521,700	304,762	263,223	258,029	272,283	99,847	105,471	104,713	101,677	99,571	98,363	104,260	97,506	104,594	111,798	122,350	122,466	127,435	134,153	75,559	112,568	127,597	133,620	141,807	117,086	129,176	139,587	171,448	147,191	160,023	166,265	173,278	211,524	228,476	524,810	326,053	231,867	285,932	288,689	314,619	332,466	301,723	313,253	332,466	288,659	285,317	294,189	301,255	272,797	226,932	241,176	270,609	118,026	127,657	118,906	117,473	116,962	124,700	126,220	113,422	115,011	128,992	129,558	134,600	131,700	123,300	135,300	156,000	125,700	82,300	89,500	107,400	77,900	87,800	96,000	102,100	67,600	76,700	85,600	93,600	93,200	-	45,200	46,700	52,100	36,000	43,200
Total Current Assets	237,429	257,761	276,711	328,195	263,601	220	243,784	276,066	464,751	432,082	410,901	437,428	500,559	857,741	863,624	830,727	1,123,645	1,183,103	1,442,307	1,567,895	870,540	1,745,225	1,480,470	349,051	237,021	224,201	197,177	174,701	163,053	140,691	126,563	133,059	215,572	210,324	196,725	191,713	185,158	198,520	28,585	33,403	24,881	16,635	14,570	17,740	23,823	17,434	21,096	23,544	32,230	26,817	28,139	31,296	37,019	35,287	43,402	50,387	68,166	59,895	69,470	67,695	93,929	85,965	96,112	101,899	109,943	115,775	132,183	427,947	235,557	64,527	113,903	112,340	132,967	172,824	108,542	131,701	172,824	125,330	118,811	124,902	130,157	105,862	56,973	63,011	83,753	48,267	61,219	51,150	53,574	52,033	57,581	57,611	44,649	44,036	55,509	58,411	56,700	54,700	44,200	58,300	78,000	46,000	52,300	63,800	84,100	54,800	64,400	75,900	85,400	50,900	59,500	67,800	73,000	74,000	-	39,900	41,600	46,800	31,300	38,600
Total Current Liabilities	16,782	18,866	29,388	98,929	98,810	135	167,853	42,578	41,665	36,297	52,497	95,805	100,111	42,300	31,370	20,438	17,002	35,695	108,985	186,777	82,249	793,344	632,850	246,979	238,868	231,683	225,840	226,995	227,129	226,131	220,347	12,240	20,836	16,253	17,949	18,157	22,779	18,433	18,621	21,005	28,939	32,461	32,571	33,017	35,439	29,879	30,419	27,206	43,643	42,454	42,315	44,570	33,488	36,680	43,598	41,434	52,172	53,047	48,202	52,884	70,614	51,701	44,612	44,311	50,968	59,832	68,058	340,501	170,810	226,415	268,412	256,029	235,211	216,712	213,481	216,216	216,712	71,529	61,470	57,258	54,049	46,290	35,154	37,823	30,535	27,610	31,681	78,315	31,726	25,032	25,455	22,847	28,415	22,455	24,380	22,391	20,700	19,200	20,800	20,000	26,900	18,700	19,700	14,500	21,700	12,200	13,100	13,000	13,800	11,100	12,600	12,800	15,700	10,900	-	7,100	8,100	7,100	5,100	5,100
Total Liab	130,707	103,808	93,213	164,759	165,183	234	273,923	311,992	479,754	461,590	469,766	549,281	652,760	549,625	547,933	524,021	702,075	696,895	760,383	834,014	699,889	1,406,222	1,238,471	257,490	252,374	237,574	230,615	230,945	230,732	230,472	224,883	221,361	229,538	229,519	235,709	230,828	233,621	229,500	36,761	40,470	55,100	56,862	60,303	67,767	77,775	76,271	86,142	92,555	113,704	120,099	122,108	129,144	80,408	122,008	124,941	131,475	138,063	126,583	141,435	154,285	181,813	145,237	141,002	141,731	144,163	185,234	194,244	455,063	298,701	483,057	524,434	513,047	425,038	407,783	404,113	407,209	407,783	247,700	237,318	233,818	230,527	210,201	199,875	203,153	196,594	37,361	40,645	87,884	175,348	169,136	170,328	164,448	168,547	145,351	145,801	142,200	160,200	176,700	153,600	151,100	167,400	118,400	68,600	66,700	73,100	61,800	64,700	63,800	67,600	59,100	64,000	63,400	65,500	60,500	-	19,100	20,400	19,400	7,500	7,300
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	399,788	0	0	0	341,290	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Total Stockholder Equity	700,913	665,402	664,892	646,317	597,485	816	802,365	793,192	821,629	812,066	786,517	745,840	709,525	697,824	695,003	661,896	767,232	850,581	1,041,453	1,079,974	560,914	699,520	619,813	497,178	418,647	424,763	409,409	398,778	370,853	370,393	391,916	392,077	304,391	292,181	69,053	35,148	26,318	44,372	64,170	65,001	49,613	44,815	39,268	30,596	26,485	21,235	18,452	19,243	8,646	2,367	5,327	5,009	-4,849	-9,440	2,656	2,145	3,744	-9,497	-12,259	-14,698	-10,365	1,954	19,021	24,534	29,115	26,290	34,232	57,402	27,352	-251,190	-238,502	-224,358	-110,419	-75,317	0	0	0	40,959	47,999	60,371	70,728	62,596	27,057	38,023	74,015	80,665	87,012	31,022	-57,875	-52,174	-45,628	-38,228	-55,125	-30,340	-16,809	-12,642	-25,600	-45,000	-30,300	-15,800	-11,400	7,300	13,700	22,800	34,300	16,100	23,100	32,200	34,500	8,500	12,700	22,200	28,100	32,700	-	26,100	26,300	32,700	28,500	35,900
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-42,280	-42,280	-42,280	-42,280	-42,280	-42,280	-42,280	-42,280	-42,280	-42,280	-42,280	-42,225	-42,134	-42,134	-42,134	-42,134	-42,134	-42,134	-42,134	-42,134	-42,134	-42,134	-42,134	-40,521	-36,446	-26,305	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-911	-11	-11	-11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16,078	18,859	21,597	24,293	26,948	29,563	32,138	0	0	39,628	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31
Begin Period Cash Flow	45,006	19,522	47,962	72,273	119,780	20,620	18,752	97,428	160,203	11,639	12,381	7,041	3,346	16,032	28,753	76,812	158,401	66,756	59,030	59,030	42,423	20,741	9,224	29,903	32,800	62,300	34,800	16,000	7,600	1,600
Capital Expenditures	53,849	17,923	8,761	4,458	2,553	11,887	7,154	28,322	10,863	4,499	4,937	8,644	78	70	522	495	440	1,783	3,604	3,604	2,783	3,161	1,974	1,085	39,500	2,400	4,300	400	200	600
Cash And Cash Equivalents Changes	0	0	-28,440	-24,311	-47,590	99,375	1,868	-78,676	-62,775	-742	0	5,340	3,695	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-17,974	57,588	2,151	25,087	8,926	-2,303	229,196	8,920	0	-3,037	17,069	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-22,052	25,484	-28,440	-24,311	-47,507	99,160	1,868	-78,676	-62,775	148,564	-742	5,340	3,695	-12,686	-12,721	-48,059	-81,589	91,645	33,280	33,280	16,607	21,682	11,517	-20,679	-2,900	-29,500	27,400	18,900	8,300	6,000
Change In Working Capital	-34,402	65,677	-52,164	-10,064	-4,215	-38,854	-11,438	-10,620	821	-10,949	-702	-2,768	-5,875	-24,738	-18,329	-1,306	-55,832	-82,661	41,192	-119,996	14,863	-6,813	-42	7,741	-8,700	-1,500	12,100	-4,000	1,400	3,200
Change Receivables	0	0	-28,616	-26,061	25,463	-29,544	-8,358	-8,525	6,489	2,367	0	1,521	-3,915	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-2,601	55,319	-28,616	-26,061	25,463	-29,544	-8,358	-8,525	6,489	-10,412	2,367	1,521	-3,915	-375	-618	0	11,537	9,433	-11,946	0	-6,875	2,442	0	0	0	0	0	0	0	0
Change To Inventory	-10,870	12,058	-427	-17,799	-2,061	-2,559	-843	-244	-401	4,369	646	1,030	1,114	-3,931	-448	0	930	1,584	-3,292	-3,292	-3,421	-1,085	1,895	81	400	-2,900	0	0	0	0
Change To Liabilities	0	-9,621	-15,060	-4,584	-4,398	-4,542	-2,639	-2,377	-6,254	-3,386	0	-6,168	-8,543	0	0	0	0	0	13,687	9,753	24,519	2,002	6,128	0	0	0	0	0	0	0
Change To Netincome	0	47,909	6,186	-1,820	-717,868	9,076	73,230	53,887	-201,819	9,480	0	4,088	-9,687	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	6,342	-4,085	-3,339	-9,572	-5,458	-5,062	-1,559	987	-1,865	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	35,643	51,370	50,946	27,966	43,731	14,718	11,714	11,290	2,627	2,657	2,663	2,727	2,790	2,212	3,134	1,052	2,615	16,217	15,275	15,275	14,280	10,472	6,573	6,973	7,400	7,700	9,800	9,400	3,700	2,500
Dividends Paid	0	5,004	15,317	3,017	2,997	0	0	0	0	0	0	0	0	0	0	0	252,557	0	0	0	1,114	0	0	0	0	0	0	0	0	0
End Period Cash Flow	22,954	45,006	19,522	47,962	72,273	119,780	20,620	18,752	97,428	160,203	11,639	12,381	7,041	3,346	16,032	28,753	76,812	158,401	92,310	92,310	59,030	42,423	20,741	9,224	29,900	32,800	62,200	34,900	15,900	7,600
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-4,272	119,927	70,037	50,128	-31,889	182,172	86,414	34,679	30,864	16,067	15,753	-8,483	-1,250	-27,137	-34,323	-21,120	-98,167	-140,304	2,150	2,150	-2,509	-28,273	-21,880	-48,440	-100,000	-69,000	-17,700	-33,700	-38,100	-14,900
Investments	-8,682	163,624	40,010	615,671	-326,817	-405,526	-57,424	-22,368	-101,752	2,342	0	10,000	9,346	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	-261,003	-164,948	-222,209	-27,323	515,404	532,326	532,326	532,326	-19,586	0	-2,500	30,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	52,154	-33,361	57,138	-2,985	629,302	143,321	12,556	-2,367	254,925	10,892	8,832	-2,674	10,173	-12,786	-8,337	-98,114	281,688	-31,743	-45,141	-45,141	-37,462	-32,596	-42,995	-59,277	-74,700	-117,900	-100,200	-37,300	-64,200	-27,100
Other Cashflows From Financing Activities	-5,496	-4,979	27,187	-789	-4,801	669,127	-5,557	5,416	8,849	207,345	2,974	8,479	30,000	14,540	24,768	-1,527	-37,750	26,788	3,946	-189	10,911	81,279	7,019	-2,169	60,200	27,500	-200	5,700	-3,500	8,900
Other Cashflows From Investing Activities	0	-960	-1,220	-379,565	796,288	-16,856	-24,599	-118,974	-108,739	-4,597	0	-8,142	-34,400	0	431	8,199	310,175	183,405	0	0	0	0	281	11,683	0	0	0	0	0	0
Other Non Cash Items	-41,257	-26,844	-7,287	27,995	-797,498	24,289	11,303	35,108	-9,491	6,286	3,857	13	1,646	-68	9,170	79,644	-327,985	-36,010	-5,572	-1,956	8,593	3,825	16,558	-2,792	15,500	45,100	64,900	-1,400	21,200	7,100
Sale Purchase Of Stock	0	-8,236	-18,446	-77,998	-453,048	-122,868	-1,966	-3,901	-489	-67,954	0	6,416	-55	-91	0	-1,613	-39,610	0	0	0	-15,867	0	0	0	0	0	0	0	0	0
Stock Based Compensation	25,743	60,285	38,783	30,727	24,515	20,846	24,915	18,893	12,458	11,270	5,666	4,067	3,351	2,325	3,365	-537	7,580	5,338	107	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-59,947	-275,990	-137,761	-310,545	-485,172	328,585	-7,523	1,515	8,360	130,025	-16,458	3,916	29,999	-159	-3,688	-3,010	-327,699	33,301	7,915	7,915	40,952	152,039	35,595	12,025	82,500	65,800	36,500	44,700	17,600	19,200
Total Cash From Operating Activities	49,577	137,850	78,798	54,586	-29,336	194,059	93,568	63,001	41,727	20,566	20,690	161	-1,172	-27,067	-33,801	-20,625	-97,727	-138,521	5,754	5,754	274	-25,112	-19,906	-47,355	-60,500	-66,600	-13,400	-33,300	-37,900	-14,300
Total Cashflows From Investing Activities	0	163,624	30,523	231,648	466,918	-423,269	-84,177	-143,192	-112,862	-4,974	-4,974	1,263	-25,132	14,540	24,768	0	343,837	196,865	0	19,611	0	0	0	14,651	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31
Begin Period Cash Flow	19,858	28,445	88,728	45,006	4,116	5,280	14,993	19,522	23,430	22,007	32,197	47,963	457,106	115,886	118,257	72,273	226,313	274,400	107,369	119,780	159,206	151,459	51,024	20,620	32,739	60,223	10,641	18,752	86,580	61,350	31,293	97,428	93,770	108,238	165,766	160,203	180,663	14,537	12,977	11,639	3,271	5,923	5,037	12,381	7,046	8,885	9,777	7,041	2,251	3,441	6,033	3,346	3,796	3,235	4,044	16,032	5,160	3,549	4,920	28,753	11,801	29,177	59,543	76,812	69,301	103,611	403,911	158,401	10,029	41,615	49,808	66,756	49,588	46,020	50,956	92,310	46,020	41,920	65,558	59,030	73,002	24,248	12,979	42,423	23,177	25,087	18,191	20,741	17,755	28,600	20,972	9,224	11,969	23,157	23,877	29,903	26,700	8,400	11,000	32,800	24,900	25,600	26,100	62,300	0	0	22,700	34,800	0	0	16,600	16,000	13,200	7,600	11,300	0	2,100	1,600
Capital Expenditures	50,745	487	203	2,414	1,171	5,289	6,588	4,875	2,195	1,772	4,794	87	4,458	89	229	63	2,553	2,553	247	301	10,887	62	66	1,000	1,936	21	112	5,085	1,789	2,186	18,663	5,684	1,865	1,278	4,463	3,257	2,563	267	45	1,624	1,003	205	3,692	37	8,011	372	242	19	38	111	5	5	1,375	5	1,384	56	15	217	106	214	41	69	189	196	71	38	245	86	191	918	484	190	268	761	548	597	761	822	1,069	952	1,542	796	207	238	281	709	676	1,495	443	191	477	863	48	182	528	327	37,400	600	1,000	500	1,300	200	500	800	600	200	3,400	100	100	200	100	400	0	300	300	100	0	200
Cash And Cash Equivalents Changes	0	0	-60,283	43,722	0	-1,164	-9,713	-4,529	0	0	-10,190	-15,766	-409,194	341,110	-2,380	46,153	-154,211	-47,992	167,154	-12,541	-39,211	7,747	100,435	30,404	-12,119	-27,484	49,582	-8,111	-67,828	25,230	30,057	-66,135	3,658	-14,468	-57,528	5,563	8,368	166,126	1,560	1,338	0	-2,652	886	-7,344	0	0	0	2,736	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-4,788	-38,783	0	2,014	3,763	12,633	0	0	3,785	-12,562	37,940	9,634	7,056	2,958	5,016	4,765	-7,630	0	12,818	-11,988	-7,180	31,437	-10,613	8,011	5,780	5,748	-2,151	1,122	-7,141	5,867	229,519	76	-1,214	815	1,987	-717	-433	2,239	0	1,714	4,006	1,213	0	0	0	-1,538	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	3,096	-8,587	-60,283	43,722	40,890	-1,164	-9,713	-4,529	-3,908	1,423	-10,190	-15,766	-409,144	341,220	-2,371	45,984	-154,040	-48,087	167,031	-12,411	-39,426	7,747	100,435	30,404	-12,119	-27,484	49,582	-8,111	-67,828	25,230	30,057	-66,135	3,658	-14,468	-57,528	5,563	-20,460	166,126	1,560	1,338	8,368	-2,652	886	-7,344	5,335	-1,839	-892	2,736	4,790	-1,190	-2,592	2,687	-450	561	-809	-11,988	10,872	1,611	-1,371	-23,833	16,952	-17,376	-30,366	-17,269	7,511	-34,310	-300,300	245,510	148,372	-31,586	-8,193	-16,948	17,168	46,290	-18,376	-41,354	46,290	4,100	-23,638	6,528	-13,972	48,754	11,269	-29,444	19,246	-1,910	6,896	-2,550	2,986	-10,845	7,628	11,748	-2,745	-11,188	-720	-6,026	3,200	18,300	-2,600	-21,800	7,900	-700	-500	-36,200	48,800	-4,400	-4,200	-12,100	27,800	-4,200	-5,300	600	3,700	5,600	13,800	11,300	-1,300	500
Change In Working Capital	-15,991	-20,832	-5,476	7,897	26,572	5,011	-16,187	50,281	-9,165	-13,806	-14,013	-15,180	-22,456	2,159	8,920	1,313	-40,482	-27,023	-71,124	134,414	-37,422	-13,707	-3,741	16,016	-10,187	3,536	-10,015	5,228	-6,193	5,447	-809	-9,065	-729	-1,403	1,827	1,126	-2,340	-4,139	-486	-3,984	3,776	-5,214	3,150	-2,414	-1,870	-194	-376	-328	-124	-603	5,669	-10,817	-3,663	-8,852	591	-12,814	-15,351	5,796	8,226	-17,000	11,589	-9,825	-725	-2,345	-8,673	-11,487	-18,442	-17,230	-184,715	-19,164	4,220	116,998	10,503	38,796	-20,424	-40,627	-97,689	-2,183	-1,094	5,673	-2,510	4,633	11,166	1,574	-5,272	1,546	-4,096	1,009	421	-3,545	9,070	-5,988	13,597	-5,033	3,674	-4,497	300	12,100	1,500	-10,500	6,700	-3,800	3,900	-8,300	13,400	-1,000	100	-400	3,000	-3,900	-200	-2,900	2,400	300	-600	900	800	2,100
Change Receivables	0	0	1,377	1,099	0	-2,658	-20,430	43,638	0	0	-5,070	2,411	-20,981	6,386	-3,068	-8,398	-8,429	-1,699	6,356	29,235	-8,164	-4,975	-4,893	-11,512	-10,267	646	-6,380	7,643	-8,114	3,380	1,813	-5,604	-653	40	1,891	5,211	3,285	-2,679	1,540	-2,451	0	-4,808	3,923	-33	0	0	0	4,118	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	2,835	-7,912	1,377	1,099	34,769	-2,658	-20,430	43,638	-19,778	-6,179	-5,070	2,411	-20,981	6,386	-3,068	-8,398	-8,429	-1,699	6,356	29,235	-8,164	-4,975	-4,893	-11,512	-10,267	646	-6,380	7,643	-8,114	3,380	1,813	-5,604	-653	40	1,891	5,211	-6,822	-2,679	1,540	-2,451	3,285	-4,808	3,923	-33	-2,432	-1,340	1,175	4,118	-4,391	-681	133	1,024	-898	-95	298	320	1,492	-1,060	1,665	-2,715	0	0	0	0	11,537	11,523	11,487	10,268	9,433	13,877	2,287	908	9,893	-11,946	9,831	12,523	0	0	1,115	4,866	2,442	2,253	4,487	-4,910	-6,974	2,797	0	2,229	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Inventory	707	-611	-13,001	2,035	1,356	962	9,696	44	2,676	-777	7,344	-9,670	-12,885	-11,891	5,726	1,251	-561	3,073	-1,750	-2,823	1,204	632	583	-4,978	1,142	2,301	-3,089	-1,197	2,150	-192	-3,055	853	-243	375	-383	-150	4,048	-254	1,132	-557	560	-343	327	102	1,828	-493	-261	-44	659	634	1,618	-1,797	10,282	0	0	47	6,855	0	0	802	0	0	0	0	31,295	930	930	930	2,098	-2,038	40	1,484	-327	-199	-2,139	-1,144	-199	397	-1,982	-1,508	-2,257	-1,199	589	-554	-1,686	-850	523	928	715	48	503	629	594	-789	452	-176	0	700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	6,960	4,081	0	7,124	-4,432	6,832	9,271	-5,386	-13,720	-7,921	-26,970	7,664	6,262	8,460	-20,273	-28,397	-63,730	108,002	4,454	-9,364	47	321	10	-496	-190	-1,963	-795	1,741	1,092	-4,289	-1,159	-1,894	1,535	-4,736	-571	343	-2,580	-1,018	0	284	-707	-2,392	0	0	0	-4,115	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,874	0	13,687	2,286	0	0	9,753	17,240	7,327	3,164	24,519	14,007	4,686	6,629	2,002	0	0	139	6,128	936	1,719	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Netincome	0	0	-2,102	14,255	-6,470	-1,004	10,742	-9,783	25,446	3,705	-12,784	2,759	-680	-2,733	-23,734	25,327	13,843	21,424	13,072	-766,207	48,098	-29,693	-3,523	-5,806	44,102	12,112	8,796	8,220	24,302	6,292	11,816	10,724	29,436	-216,038	-16,971	3,369	6,117	5,158	3,680	3,696	0	2,126	-1,139	2,376	0	0	0	532	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	-812	-812	-812	-417	-1,021	-233	-1,525	226	982	-3,768	-3,805	-2,674	875	2,265	-250	2,081	-7,284	-4,119	-115	-3,867	-32,185	32,185	402	1,085	-356	745	526	385	-659	-25	987	0	0	0	-1,865	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	8,921	8,542	9,060	9,120	11,134	13,505	13,087	13,644	12,948	12,613	12,292	13,093	12,816	4,548	4,222	6,380	22,036	8,544	8,065	5,086	3,297	5,408	3,011	3,002	4,133	2,017	2,585	2,979	2,968	2,934	2,813	2,575	687	644	646	650	659	661	669	668	656	668	669	670	749	638	662	678	691	750	785	564	95	669	703	745	-736	1,957	932	981	238	1,248	-241	-193	364	399	938	914	2,688	4,169	4,633	4,727	4,777	3,945	4,724	4,459	3,945	3,870	3,649	3,811	3,582	3,531	3,540	3,627	5,356	1,773	1,719	1,624	1,331	1,710	1,835	1,697	-5,603	4,126	4,027	4,423	-3,200	4,100	3,400	3,100	2,300	1,800	1,800	1,800	2,700	2,500	2,300	2,300	2,500	4,600	1,200	1,100	1,200	700	1,400	400	300	400
Dividends Paid	0	0	9,078	4,917	5,201	628	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	514	185	252,742	252,742	252,742	0	0	0	0	0	0	0	0	0	0	0	0	17,523	0	0	251	93,413	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	22,954	19,858	28,445	88,728	45,006	4,116	5,280	14,993	19,522	23,430	22,007	32,197	47,962	457,106	115,886	118,257	72,273	226,313	274,400	107,369	119,780	159,206	151,459	51,024	20,620	32,739	60,223	10,641	18,752	86,580	61,350	31,293	97,428	93,770	108,238	165,766	160,203	180,663	14,537	12,977	11,639	3,271	5,923	5,037	12,381	7,046	8,885	9,777	7,041	2,251	3,441	6,033	3,346	3,796	3,235	4,044	16,032	5,160	3,549	4,920	28,753	11,801	29,177	59,543	76,812	69,301	103,611	403,911	158,401	10,029	41,615	49,808	66,756	92,310	32,580	50,956	92,310	46,020	41,920	65,558	59,030	73,002	24,248	12,979	42,423	23,177	25,087	18,191	20,741	17,755	28,600	20,972	9,224	11,969	23,157	23,877	29,900	26,700	8,400	11,000	32,800	24,900	25,600	26,100	48,800	-4,400	-4,200	22,700	27,800	-4,200	-5,300	16,600	3,700	13,200	13,800	11,300	-1,300	2,100
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-42,680	7,159	-285	31,534	52,301	15,200	5,290	47,136	25,447	18,253	20,377	10,754	-3,921	12,745	24,382	16,922	-9,892	-6,197	-61,058	45,258	21,685	27,082	73,644	59,761	29,374	27,629	10,274	19,137	19,204	16,337	-8,292	7,430	11,800	9,159	5,583	4,322	7,683	3,468	3,963	953	11,031	-564	3,245	2,041	-5,839	-1,282	-974	-388	7,055	-1,166	-8,045	906	75	-7,679	-3,601	-15,932	-1,274	-11,558	2,844	-24,335	6,152	-13,517	-4,160	-9,595	-8,858	-14,269	-29,605	-45,435	-84,260	-28,939	-6,931	-20,174	11,804	27,279	-8,453	-3,194	27,279	-7,856	-12,705	-4,568	7,634	-3,407	3,249	-9,985	-9,843	-4,235	-12,559	-1,636	-3,914	-7,147	3,186	-14,005	-9,198	-15,766	-9,286	-14,190	-47,600	-14,900	-15,000	-22,500	-17,800	-18,100	-12,200	-20,900	12,400	-10,400	-11,400	-8,300	-6,200	-10,200	-8,700	-8,600	-4,500	-3,200	-4,500	-3,100	-4,300	-3,000
Investments	-10,284	-19,503	7,676	12,833	-7,284	24,418	44,406	118,756	-32,657	-16,445	20,353	68,759	-25,264	345,825	-13,952	309,062	-62,264	181,991	268,235	-714,779	295,081	-81,704	-586,562	-32,341	-11,780	-56,517	36,454	-25,581	-84,940	7,264	37,229	18,779	-9,611	-25,087	-67,513	459	846	340	530	626	0	0	0	0	0	0	0	8,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	-76,854	-13	-13	-37,444	-59,947	-163,356	-163,369	-2,379	-49,946	-108,426	-18,999	-28,548	-28,548	-203,210	-203,210	-27,323	-27,323	-27,323	-107,790	52,129	571,065	728,215	0	728,215	0	0	0	0	0	0	0	0	0	0	-3,362	236,872	-3,511	-3,436	0	-3,291	-3,219	-9,714	0	0	0	-1,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	18,188	-10,273	2,290	41,949	-17,485	404	-895	-15,385	-5,416	13,723	30,725	18,106	5,761	-6,701	22,086	-24,131	-7,365	-15,251	-14,419	666,337	-42,482	67,362	73,162	45,279	-7,010	8,429	6,058	5,079	-3,126	645	-5,763	5,877	8,448	224,539	22,027	-89	6,732	776	1,287	2,097	1,869	1,965	3,694	1,304	2,586	-707	-4,066	-487	5,502	-3,901	-914	9,486	2,348	-11,854	-291	-2,989	2,569	1,051	-4,475	-7,482	-69,627	-18,125	-6,429	-3,933	5,938	1,248	181	274,321	141,364	-14,920	-15,958	-142,229	-2,722	-10,997	-8,924	-18,472	-10,997	-6,789	-14,216	-13,139	5,943	-11,088	-11,997	-20,320	-6,728	-7,047	-12,246	-6,575	-13,055	-7,744	-10,615	-11,581	-12,937	-14,926	-16,459	-14,955	-22,800	-18,300	-19,000	-14,600	-40,700	-46,200	-17,500	-13,500	-68,100	-11,500	-10,500	-10,100	-11,800	-8,400	-10,000	-7,100	-8,400	-5,800	-6,500	-6,300	-7,400	-6,900
Other Cashflows From Financing Activities	-1,166	-4,304	9,084	9,072	-5,286	-3,168	519	-7,052	13,352	1,994	41	20,988	5,730	-3,706	-5	-2,808	25,572	-2,800	741	-991	-81,055	58,917	664,361	5,119	-7,255	1,404	-5	-1,667	-1,896	1,629	1,469	1,013	10,470	1,460	4,649	781	438	164,736	453	3,195	629	1,244	860	326	10,979	-2,368	-242	7,500	-55	-137	5,000	25,000	1,028	8,276	1,356	3,880	12,074	13,052	-4,231	3,873	1,267	-356	-397	514	1,810	-549	-278,495	-38,282	28,163	-283	-665	253	2,753	-2,270	-7	-30	-8,378	607	4,595	1,655	4,074	-382	3,788	300	222,914	1,184	-50,381	-428	370	-180	-768	7,597	-939	-579	-334	-317	100	60,100	500	-500	29,500	-800	-700	-500	1,700	-800	-600	-500	4,200	-500	-600	2,600	-500	-400	-200	9,700	-300	-300
Other Cashflows From Investing Activities	0	0	83	130	0	-913	33	33	-1,355	-1,355	3,779	-3,644	-352,480	-13,754	-12,805	-526	1,638	-12,474	-2,432	809,556	-18,892	3,452	-176	-1,240	-22,460	3,059	2,859	-4,998	-1,720	-1,424	-17,529	-98,301	-1,799	-1,278	-4,693	-3,247	-889	-268	-51	-1,618	0	-140	-3,571	3	0	0	0	-4,536	0	0	0	0	0	0	0	629	431	261	37	0	8,199	8,138	8,052	8,008	310,175	338,660	291,890	280,428	183,405	72	46	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	67	98	281	238	143	629	11,683	11,054	10,439	9,955	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-13,709	15,318	-3,163	-39,703	-42,187	1,617	3,119	10,607	19,256	-3,796	-21,485	-1,262	-5,817	15,420	-19,734	38,126	-4,891	19,131	16,451	-828,189	117,580	-49,337	-26,001	-17,953	-2,287	4,789	4,928	3,873	11,791	4,006	13,803	5,508	4,936	1,078	-18,477	2,972	2,426	2,625	-441	1,676	4,079	628	-2,178	1,328	1,406	-1,803	1,316	-906	-260	1,726	-651	15,134	-6,702	11,764	-4,568	-562	30,728	-20,599	-749	-210	72,579	13,254	3,424	4,898	-325,185	-4,391	-12,037	6,421	-40,051	1,894	658	871	-486	-3,704	0	0	0	-1,932	25	39	2,161	313	747	5,372	-2,918	202	2,740	3,801	7,832	2,623	3,373	2,730	-4,207	249	0	1,166	15,500	-12,200	100	0	15,200	29,900	100	-100	65,000	-200	100	0	0	-2,300	200	700	300	1,900	1,500	2,000	2,000	1,600
Sale Purchase Of Stock	0	0	-32	-4,155	-2,218	-96	-60	347	0	0	1,091	26,493	-4,711	909	1,129	-73,287	-81,942	-181,189	-38,332	-151,585	-70,141	7,011	-50,832	-1,895	-1,313	1,494	2,015	355	-198	2,628	1,469	-502	-9,000	1,460	4,649	781	-29,431	-26,410	453	3,195	0	1,243	860	326	5,313	3,181	0	160	55	2	0	-55	-91	0	0	0	0	0	0	0	0	0	0	-1,613	-4,075	-10,141	0	253,274	0	0	0	0	0	0	0	0	0	0	0	0	20,867	0	0	-15,867	5,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	5,721	6,884	7,207	5,931	29,145	12,597	9,499	9,044	10,408	9,754	10,216	8,405	9,975	7,740	7,359	5,653	6,300	6,297	6,571	5,347	6,009	5,470	4,812	4,555	8,998	5,248	4,624	6,045	5,203	5,331	4,241	4,118	2,947	2,836	3,761	2,914	2,475	3,702	3,026	2,067	1,517	1,533	1,492	1,124	951	1,013	1,394	709	705	950	1,244	452	311	557	833	624	924	741	880	820	3,607	0	0	996	7,580	0	0	5,554	5,338	0	0	814	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	5,315	3,270	-67,757	-775	-5,298	-40,829	-59,442	-170,421	4,164	-385	-49,905	-91,635	-27,529	-3,706	-5	-279,305	-83,693	-211,312	-37,591	-152,576	-347,085	58,917	613,529	3,224	-7,255	1,404	-5	-1,667	-2,094	1,629	1,469	511	1,470	1,460	4,649	781	-28,995	162,319	-3,058	-241	-2,663	-2,048	-2,359	-9,388	3,235	1,439	82	-840	52	2	5,000	24,945	-178	-41	52	8	87	-100	-90	-3,585	-201	-331	-385	-2,093	-4,581	-10,430	-277,263	-35,425	32,695	179	386	41	-24	-4,589	-153	818	-4,589	2,280	6,477	3,747	4,619	48,294	4,342	-16,303	131,085	1,958	17,477	1,519	2,177	903	1,996	30,519	670	154	7,567	3,634	14,300	63,500	5,000	-300	47,100	14,800	3,700	200	32,800	600	700	3,100	41,100	-800	300	4,100	3,100	4,600	-300	19,900	-200	-200
Total Cash From Operating Activities	8,065	7,646	-82	33,948	53,472	20,489	11,878	52,011	27,642	20,025	20,377	10,754	537	12,745	24,382	16,922	-7,339	-6,197	-61,058	45,258	32,572	27,082	73,644	60,761	31,310	27,650	10,386	24,222	20,993	18,523	10,371	13,114	13,665	10,437	10,046	7,579	10,246	3,735	4,008	2,577	12,034	-359	6,937	2,078	2,172	-910	-732	-369	7,017	-1,055	-8,045	911	-1,300	-7,674	-2,217	-15,876	-1,289	-11,341	2,950	-24,121	6,193	-13,448	-3,971	-9,399	-8,787	-14,231	-29,360	-45,349	-84,069	-28,021	-6,447	-19,984	12,072	28,040	-7,905	-2,597	28,040	-7,034	-11,636	-3,616	9,176	-2,611	3,456	-9,747	-9,562	-3,526	-11,883	-141	-3,471	-6,956	3,663	-13,142	-9,150	-15,584	-8,758	-13,863	-10,200	-14,300	-14,000	-22,000	-16,500	-18,300	-11,700	-20,100	13,000	-10,200	-8,000	-8,200	-6,300	-10,000	-8,800	-8,200	-4,500	-2,900	-4,200	-3,000	-4,300	-2,800
Total Cashflows From Investing Activities	0	0	7,556	10,549	7,556	19,176	37,851	113,881	-35,713	-18,217	19,338	65,115	-382,202	332,071	-26,757	308,536	-63,179	169,517	265,803	94,777	275,302	-78,252	-586,738	-33,581	-36,174	-56,538	39,201	-30,666	-86,727	5,078	18,217	-79,760	-11,477	-26,365	-75,020	-2,797	-1,003	72	610	-998	-4,974	-245	-3,692	-34	1,263	1,335	3,703	3,945	-25,132	-22,853	-22,716	0	14,540	13,512	5,236	3,880	24,768	12,694	0	3,873	0	0	0	0	343,837	322,958	332,607	326,284	196,865	0	863	2,995	0	0	0	0	19,611	0	0	6,397	0	3,148	77	0	0	0	0	0	0	0	0	0	14,651	8,916	4,674	4,203	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31	1997-12-31	1996-12-31	1995-12-31	1994-12-31
Cost Of Revenue	11,561	52,827	62,176	30,419	11,347	6,337	5,366	5,571	5,807	9,136	5,733	3,601	4,909	6,458	15,235	41,703	58,727	22,642	39,804	39,804	31,618	20,306	13,947	1,618	3,100	-7,700	-9,800	-9,400	-3,700	24,700
Depreciation And Amortization	35,643	34,237	38,307	23,442	-798,821	15,792	12,120	10,643	2,627	2,657	2,663	2,727	2,790	2,212	3,134	1,052	2,615	16,217	15,275	15,275	14,280	10,472	6,573	6,973	7,400	7,700	9,800	9,400	3,700	2,500
Discontinued Operations	0	-28,142	-19,215	-9,583	-9,583	0	0	731	731	2,588	0	2,147	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	15,580	-25,503	78,895	8,550	-5,721	163,727	70,656	49,283	3,565	24,272	17,957	127	-4,560	-39,909	-34,163	46,958	-60,938	-173,220	-52,911	-37,371	-13,086	-20,915	-14,774	-45,057	-50,600	-26,600	30,500	-36,600	8,900	-15,400
Ebitda	51,223	8,734	117,202	31,992	-804,542	179,519	82,776	59,926	6,192	26,929	20,620	2,854	-1,770	-37,697	-31,029	48,010	-58,323	-157,003	-37,636	-22,096	1,194	-10,443	-8,201	-38,084	-43,200	-18,900	40,300	-27,200	12,600	-12,900
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	-600	-32,400	731	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	119,753	143,418	214,957	156,000	108,935	245,116	135,736	103,402	66,107	55,402	43,241	27,787	25,128	23,538	23,705	27,315	12,894	118,318	123,708	123,708	109,522	76,334	62,394	46,492	37,800	25,400	61,500	46,200	28,200	-11,400
Income Before Tax	63,660	36,011	47,298	-10,538	796,639	173,330	57,231	7,960	35,329	11,302	9,207	-3,865	-2,930	-15,403	-9,872	-97,515	-53,456	-174,273	-44,908	-44,908	-37,462	-32,596	-31,500	-46,707	-62,000	-112,600	-92,100	-29,200	-58,700	-26,400
Income Tax Expense	9,841	41,230	-10,288	-7,553	167,337	30,009	44,675	10,327	-219,596	410	374	-1,191	-13,103	-2,617	-7,924	-55	-18,697	-38,414	233	233	18,284	8,445	19,858	26,494	18,400	48,300	69,400	4,400	39,300	6,200
Interest Expense	656	1,799	18,740	27,420	35,745	48,276	11,400	12,178	11,802	4,860	2,077	3,305	2,508	58	270	202	735	10,614	11,142	0	10,970	6,295	0	0	0	0	0	0	0	0
Interest Income	7,041	2,046	886	8,078	28,430	13,999	13,448	35,310	16,945	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	-2,380	-1,132	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	52,154	-5,219	57,138	-2,985	629,302	143,321	12,556	-1,636	257,305	12,024	11,421	-527	10,176	-12,515	-1,948	-98,114	281,688	-31,743	-45,141	-45,141	-37,462	-32,596	-42,995	-72,376	-74,700	-117,900	-100,200	-37,300	-64,200	-27,100
Net Income Applicable To Common Shares	0	-33,361	57,586	-2,985	629,302	143,321	12,556	-1,636	229,824	11,420	8,832	-527	10,173	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	21,097	-5,219	57,586	-2,985	629,302	143,321	12,556	-2,367	227,444	8,832	0	-3,865	9,712	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	6,276	247	-18,740	-19,342	-7,315	-34,277	-11,400	-12,178	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	-11,971	-8,963	25,308	57,879	555	-23,747	19,802	-3,660	0	-1,134	-352	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	1,032	1,020	1,084	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	9,821	-25,503	78,895	8,550	-5,721	163,727	68,076	43,885	27,329	19,626	14,943	574	-698	-29,304	-9,967	-97,276	-60,175	-168,770	-37,371	-37,371	-19,178	-24,151	-23,137	-45,882	-56,300	-69,600	-30,800	-32,900	-24,900	-20,900
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	121,493	193,208	198,238	177,688	126,003	87,726	73,026	64,056	43,565	43,828	32,990	30,499	30,177	51,790	70,316	52,591	73,069	309,730	200,883	200,883	160,318	120,791	99,478	93,992	97,200	87,300	82,500	69,700	49,400	34,200
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	37,856	34,237	47,167	27,966	43,731	14,718	11,714	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Research Development	24,537	36,082	69,012	59,392	55,908	27,863	26,887	21,221	13,380	12,122	9,274	10,790	10,291	22,067	39,870	30,770	44,623	41,926	65,204	65,204	67,679	58,807	51,104	51,287	59,400	70,700	72,400	59,500	41,400	0
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15,235	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	52,790	70,062	57,483	64,435	41,884	37,734	28,653	26,621	24,378	22,570	17,984	16,108	14,977	29,723	30,446	23,785	30,410	248,281	95,875	95,875	61,021	41,678	34,427	34,114	27,300	16,600	10,100	10,200	0	0
Tax Provision	49,606	41,230	-10,288	-7,553	167,337	30,009	44,675	10,327	-192,115	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	109,932	140,381	136,062	147,269	114,656	81,389	67,660	58,485	37,758	34,692	27,258	26,898	25,268	51,790	70,316	52,591	73,069	287,088	161,079	161,079	128,700	100,485	85,531	92,374	94,100	95,000	92,300	79,100	53,100	9,500
Total Other Income Expense Net	53,839	61,514	-31,597	-19,088	802,360	43,880	-10,845	-36,957	6,980	-9,408	-6,776	-4,754	-50	11,147	-347	-72,234	763	4,450	15,540	15,540	-6,092	-3,236	-8,363	-825	-5,700	-43,000	-61,300	3,700	-33,800	-5,500
Total Revenue	131,314	196,245	277,133	186,419	120,282	251,453	141,102	108,973	71,914	64,538	48,974	31,388	30,037	23,538	38,940	27,315	12,894	140,960	163,512	163,512	141,140	96,640	76,341	48,110	40,900	17,700	51,700	36,800	24,500	13,300

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31	1998-09-30	1998-06-30	1998-03-31	1997-12-31	1997-09-30	1997-06-30	1997-03-31	1996-12-31	1996-09-30	1996-06-30	1996-03-31	1995-12-31	1995-09-30	1995-06-30	1995-03-31	1994-12-31	1994-09-30	1994-06-30	1994-03-31
Cost Of Revenue	1,664	3,485	1,669	3,717	21,614	14,153	12,361	4,699	11,984	11,446	30,593	8,153	11,739	6,353	7,644	4,683	1,937	3,147	2,405	3,858	2,955	1,460	1,134	788	1,738	2,385	903	341	2,896	999	720	955	884	1,250	2,600	1,074	4,002	1,496	1,186	2,451	1,317	2,538	1,214	663	2,328	683	435	155	2,058	703	1,623	525	6,526	7,339	9,154	-15,235	-15,235	15,235	3,633	2,523	8,031	10,828	10,678	12,166	13,439	13,795	13,720	5,874	5,874	5,800	10,266	9,740	8,308	10,044	10,667	11,065	10,044	11,011	9,926	8,823	8,667	8,565	7,766	6,620	5,519	5,646	4,681	4,460	4,386	3,645	2,140	1,903	7,866	-1,888	-2,017	-2,343	5,500	-900	-1,000	-500	-2,300	-1,800	-1,800	-1,800	-2,700	-2,500	-2,300	-2,300	-2,500	-4,600	-1,200	-1,100	-1,200	-900	-	-700	6,200	6,400	6,200	5,900
Depreciation And Amortization	8,921	8,238	8,539	-30,994	-35,709	11,818	11,824	11,813	11,776	12,613	11,779	11,786	12,157	3,875	3,875	3,535	6,304	3,552	3,505	3,503	3,483	5,408	3,305	3,002	3,994	2,017	2,706	2,979	2,731	2,706	2,813	2,524	687	644	646	650	659	661	669	668	656	668	669	670	749	638	662	678	691	750	785	564	95	669	703	745	-736	1,957	932	981	238	1,248	-241	-193	364	399	938	914	2,688	4,169	4,633	4,727	4,777	3,945	4,724	4,459	3,945	3,870	3,649	3,811	3,582	3,531	3,540	3,627	5,356	1,773	1,719	1,624	1,331	1,710	1,835	1,697	-5,603	4,126	4,027	4,423	-3,200	4,100	3,400	3,100	2,300	1,800	1,800	1,800	2,700	2,500	2,300	2,300	2,500	4,600	1,200	1,100	1,200	900	-	700	1,400	400	300	400
Discontinued Operations	0	0	0	0	-2,951	-2,951	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,462	4,386	-2,924	731	731	0	0	0	731	0	0	0	0	0	2,397	191	0	0	0	1,871	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Ebit	953	15,220	-5,974	14,205	-20,099	1,559	1,440	-6,608	9,390	17,761	52,603	-8,346	-23,228	3,528	8,903	3,788	-18,659	-5,158	-4,130	-799,051	33,149	90,743	109,033	38,277	28,628	18,518	13,840	10,356	20,431	6,507	5,456	16,890	10,832	6,986	-16,761	3,798	10,357	4,855	2,273	7,456	10,136	3,388	-179	5,951	6,796	-3,460	-394	-1,841	5,706	-1,116	-1,252	-2,758	-3,155	-15,616	-3,510	-4,242	2,141	-21,908	-5,379	-7,179	70,891	-6,691	-5,093	-11,715	-7,171	-9,314	-14,868	-29,094	-141,468	-11,488	-13,163	-140,456	-3,556	-28,226	-6,507	-15,770	-11,955	-3,645	-11,246	-10,253	10,782	-7,931	-8,691	-7,245	-9,565	-6,527	-9,146	-80	5,067	-4,363	-7,613	-7,865	-11,114	-11,564	-13,213	-9,167	-6,200	-14,900	-16,800	-12,700	-8,900	11,100	-16,200	-12,600	62,200	-11,100	-10,300	-10,200	-11,400	-7,700	-9,800	-7,200	-8,600	-8,900	-	-2,800	-3,400	-3,500	-4,300	-4,300
Ebitda	9,874	23,458	2,565	-16,789	-55,808	13,377	13,264	5,205	21,166	30,374	64,382	3,440	-11,071	7,403	12,778	7,323	-12,355	-1,606	-625	-795,548	36,632	96,151	112,338	41,279	32,622	20,535	16,546	13,335	23,162	9,213	8,269	19,414	11,519	7,630	-16,115	4,448	11,016	5,516	2,942	8,124	10,792	4,056	490	6,621	7,545	-2,822	268	-1,163	6,397	-366	-467	-2,194	-3,060	-14,947	-2,807	-3,497	1,405	-19,951	-4,447	-6,198	71,129	-5,443	-5,334	-11,908	-6,807	-8,915	-13,930	-28,180	-138,780	-7,319	-8,530	-135,729	1,221	-24,281	-1,783	-11,311	-8,010	225	-7,597	-6,442	14,364	-4,400	-5,151	-3,618	-4,209	-4,754	-7,427	1,544	6,398	-2,653	-5,778	-6,168	-16,717	-7,438	-9,186	-4,744	-9,400	-10,800	-13,400	-9,600	-6,600	12,900	-14,400	-10,800	64,900	-8,600	-8,000	-7,900	-8,900	-3,100	-8,600	-6,100	-7,400	-8,000	5,400	-2,100	-2,000	-3,100	-4,000	-3,900
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-600	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Gross Profit	26,437	29,383	24,697	40,262	28,768	51,935	45,058	40,994	60,489	53,389	54,082	46,997	58,251	35,495	33,776	28,478	25,066	21,661	22,582	39,626	56,635	44,203	88,909	55,369	48,726	30,990	27,092	28,926	35,289	20,620	18,801	28,693	20,308	16,451	15,818	13,528	18,996	13,477	9,422	13,507	13,420	10,467	8,366	10,988	11,307	5,692	5,307	5,481	10,878	5,038	5,840	3,371	3,940	7,802	5,838	5,958	29,212	-7,334	7,594	9,470	12,389	5,248	4,804	4,874	5,770	5,479	1,410	235	28,256	30,907	38,181	41,216	40,760	26,899	35,132	25,920	26,899	38,486	30,534	27,789	48,941	22,718	21,360	16,503	21,804	19,620	14,485	20,426	18,257	15,529	15,349	15,132	5,733	13,958	12,788	14,012	6,900	10,700	9,400	10,800	6,600	5,700	6,200	6,900	24,500	12,700	12,200	12,100	12,100	14,700	9,700	9,900	9,100	7,500	5,400	5,300	-1,400	-2,700	-3,700	-3,600
Income Before Tax	17,097	-15,344	3,171	55,536	24,140	857	-636	-20,140	-7,026	15,259	33,301	5,764	3,370	-11,612	28,119	-30,415	-8,175	-19,871	-18,028	842,713	-56,789	79,226	95,579	55,312	30,665	12,071	8,300	6,193	7,230	804	-9,644	9,571	5,826	7,284	22,292	-74	7,012	901	1,241	2,150	2,008	2,025	3,804	1,370	950	-52	-3,728	-522	5,997	-3,884	-773	-4,292	-1,587	-11,436	335	-2,715	1,034	1,055	-4,476	-7,482	-73,964	-6,134	-5,919	-11,498	-8,240	-7,222	-11,911	-26,083	4,506	-16,969	-15,940	-142,212	69,963	-94,410	-8,907	-18,452	17,530	-4,125	-14,216	-13,139	-37,462	-11,087	-11,997	-20,320	-32,596	-7,047	-9,804	-4,614	-10,161	-4,755	-7,717	-8,867	-8,180	-12,350	-13,941	-12,235	-17,200	-15,300	0	0	-38,900	-44,900	0	0	-66,000	-9,500	-8,500	-8,000	-9,800	-6,300	-8,000	-5,000	-6,200	-6,500	-	-5,400	-6,200	-6,100	-7,100	-6,900
Income Tax Expense	-1,091	-2,552	881	11,922	38,674	453	259	-4,755	-2,058	1,536	2,576	-12,342	-2,391	-4,911	6,033	-6,284	-810	-4,620	-3,609	176,376	-14,307	11,864	22,419	10,033	37,675	3,645	2,242	1,114	10,355	160	-3,881	3,694	-515	-217,255	265	15	279	124	-47	53	139	60	110	66	-1,636	142	338	-35	495	22	141	-13,778	-3,935	419	625	274	-1,535	-748	-4,476	-2,366	-234	2,990	-1,030	-1,781	-2,918	-2,360	-4,225	-9,194	-36,124	-828	18	17	5	-56	17	20	196	2,904	2,951	2,873	-43,404	2,893	2,927	7,757	-25,868	260	2,771	4,228	10,508	3,185	2,950	3,215	16,389	2,969	2,882	4,254	11,100	3,200	2,200	1,900	16,800	29,400	1,200	900	66,200	1,300	1,000	1,000	1,200	1,400	1,100	1,000	1,000	800	41,500	1,700	1,700	1,500	1,700	1,300
Interest Expense	131	1	2,036	1,195	1	332	438	655	4,284	4,439	4,883	5,831	6,390	5,278	4,244	8,548	8,834	8,993	9,012	8,906	20,143	11,200	13,454	2,605	11,400	2,822	2,860	2,941	12,178	3,116	2,969	3,005	11,802	2,930	2,969	2,973	4,860	1,516	181	248	2,077	394	453	912	4,944	838	847	792	715	700	674	423	19	8	13	18	13	21	42	194	202	45	39	52	735	143	90	370	10,614	2,547	6,156	6,067	12,458	11,142	3,002	3,127	3,018	3,145	3,140	3,091	10,970	2,766	2,688	2,682	6,295	147	2,814	2,252	3,243	3,464	3,449	3,445	3,234	3,221	3,203	3,461	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Interest Income	1,693	2,262	2,320	1,435	1,023	591	298	134	188	169	233	296	388	991	1,969	4,730	5,840	7,396	9,285	14,296	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,537	-843	-325	-503	-304	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Net Income	18,188	-12,792	2,290	41,949	-14,534	404	-895	-15,385	-4,968	13,723	30,725	18,106	5,761	-6,701	22,086	-24,131	-7,365	-15,251	-14,419	666,337	-42,482	67,362	73,160	45,279	-7,010	8,426	6,058	5,079	-3,125	644	-5,763	6,608	6,341	224,539	23,564	754	7,056	1,280	1,592	2,097	1,869	1,965	6,091	1,495	1,063	-194	-2,267	1,384	5,502	-3,906	-914	9,490	4,503	-11,843	-283	-2,750	3,036	1,803	-1,668	-5,116	-69,627	-18,125	-6,429	-3,933	5,938	1,248	181	274,321	141,364	-14,918	-15,958	-142,229	-2,722	-10,997	-8,924	-18,472	-10,997	-6,789	-14,216	-13,139	5,943	-11,087	-11,997	-20,320	-6,728	-7,047	-12,246	-6,575	-13,055	-7,744	-10,615	-11,581	-26,036	-14,926	-16,459	-14,955	-22,800	-18,300	-19,000	-14,600	-40,700	-46,300	-17,400	-13,500	-68,100	-11,600	-10,400	-10,100	-11,800	-8,400	-10,000	-7,100	-8,400	-8,500	-41,500	-5,800	-6,500	-6,300	-7,400	-6,900
Net Income Applicable To Common Shares	0	0	2,290	41,949	-17,485	404	-895	-15,385	-4,968	13,723	30,725	18,106	5,761	-6,701	22,086	-24,131	-7,365	-15,251	-14,419	666,337	-42,480	67,362	73,160	45,279	-7,007	8,426	6,058	5,079	-3,125	1,052	-6,170	6,608	-19,033	224,539	23,564	754	1,869	1,280	1,592	2,097	1,869	1,965	6,091	1,495	2,586	0	0	1,133	4,686	-3,756	-914	9,621	2,348	0	0	0	2,566	1,058	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	17,334	0	0	0	7,948	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Net Income From Continuing Ops	18,188	-12,792	2,290	43,614	-14,534	404	-895	-15,385	-4,968	13,723	30,725	18,106	5,761	-6,701	22,086	-24,131	-7,365	-15,251	-14,419	666,337	-42,480	67,362	73,160	45,279	-7,007	8,426	6,058	5,079	-3,125	1,051	-6,170	5,877	-19,033	224,539	22,027	-89	1,803	777	1,288	2,097	0	1,965	3,694	1,370	0	0	0	-773	0	-3,756	-914	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Net Interest Income	1,562	2,262	2,036	1,195	783	259	-140	-655	-4,284	-4,270	-4,650	-5,535	-6,002	-5,278	-4,244	-3,818	-2,994	-1,597	273	-2,997	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Non Operating Income Net Other	0	0	5,438	41,571	0	553	271	-10,045	0	3,992	-7,555	6,880	-1,450	-9,090	27,232	-25,655	10,838	-5,720	-4,886	25,076	-68,919	67,064	38,858	20,876	5,092	-1,600	-1,855	-1,082	-9,119	-1,139	-10,969	-2,520	-2,261	1,617	20,896	-450	-4,102	-1,115	64	-2,702	0	-651	2,743	-1,650	0	0	0	784	0	215	711	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,291	-145	-358	244	1,020	0	0	0	1,084	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Operating Income	-3,358	-122	-1,983	14,205	-20,099	1,559	1,440	-6,608	9,390	15,706	45,739	4,715	11,210	3,747	7,100	3,788	-10,179	-5,158	-4,130	826,543	33,149	23,362	70,175	37,041	28,350	16,493	13,015	10,216	19,355	5,466	4,376	15,096	11,016	8,597	4,365	3,349	9,637	3,532	1,358	5,100	6,425	3,070	1,514	3,932	4,392	-1,322	-1,730	-765	5,728	-3,399	-810	-2,218	-5,962	-15,675	-3,628	-4,026	1,255	774	-4,657	-7,318	-73,389	-6,355	-5,633	-11,899	-8,042	-8,724	-14,366	-29,043	4,894	-15,065	-10,990	-137,101	-679	-11,955	-6,507	-15,770	-11,955	-3,885	-11,265	-10,266	10,650	-8,194	-9,070	-12,563	-5,542	-6,787	-9,475	-2,347	-2,547	-4,559	-7,665	-8,366	-9,647	-11,957	-13,577	-10,701	-11,700	-15,100	-16,800	-12,700	-23,900	-16,900	-16,200	-12,600	-1,900	-10,300	-9,400	-9,100	-10,600	-7,000	-8,900	-6,100	-7,400	-7,700	5,400	-4,100	-4,800	-4,800	-5,700	-5,600
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Other Operating Expenses	31,459	31,911	28,349	29,774	70,481	65,452	57,888	54,999	59,739	49,129	38,936	50,435	75,894	38,101	34,320	29,373	37,182	29,966	29,117	29,738	26,441	22,301	19,868	19,116	22,114	16,882	14,980	19,051	18,662	15,908	14,771	14,308	9,942	8,759	13,835	11,030	12,800	11,259	9,114	10,654	8,110	9,708	7,542	7,630	9,087	7,712	7,225	6,475	8,932	6,858	8,715	6,691	8,850	23,477	9,466	10,410	13,147	27,571	12,301	17,279	13,778	11,603	10,437	16,773	13,812	14,203	15,776	29,278	29,236	51,772	59,437	188,057	49,747	48,898	52,306	52,755	48,898	53,382	51,725	46,878	46,958	39,477	38,196	35,686	32,865	32,053	28,641	27,233	25,190	23,733	25,154	25,401	23,246	24,027	24,348	22,370	24,100	24,900	25,200	23,000	28,200	20,800	20,600	17,700	23,700	20,500	19,300	18,900	20,200	17,100	17,400	14,900	15,300	14,300	-	8,700	9,600	8,500	8,200	7,900
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Reconciled Depreciation	8,921	8,238	8,539	8,539	8,539	13,505	11,824	11,813	11,776	12,613	11,779	11,786	12,816	4,548	4,222	6,380	22,036	8,544	8,065	5,086	3,297	5,408	3,011	3,002	4,133	2,017	2,585	2,979	2,968	2,934	2,813	2,575	687	644	646	650	659	661	669	668	656	668	669	670	749	638	662	678	691	750	785	564	95	669	703	745	-736	1,957	932	981	238	1,248	-241	-193	364	399	938	914	2,688	4,169	4,633	4,727	4,777	3,945	4,724	4,459	3,945	3,870	3,649	3,811	3,582	3,531	3,540	3,627	5,356	1,773	1,719	1,624	1,331	1,710	1,835	1,697	-5,603	4,126	4,027	4,423	-3,200	4,100	3,400	3,100	2,300	2,700	1,800	1,800	2,700	2,500	2,300	2,300	2,500	4,600	1,200	1,100	1,200	-	-	700	1,400	400	300	400
Research Development	5,488	5,532	6,854	6,663	9,197	22,036	19,118	20,307	18,243	16,938	15,953	17,879	21,916	12,853	12,732	11,891	18,664	13,742	12,213	11,289	8,840	5,483	6,135	7,407	8,633	4,759	4,822	8,673	6,408	6,305	4,507	4,004	2,870	2,538	4,010	3,962	3,199	3,021	2,689	3,131	2,374	2,414	2,022	2,465	2,476	2,647	2,850	2,817	2,598	2,471	3,237	1,986	3,155	4,935	6,602	7,362	10,126	9,921	9,470	10,462	11,063	6,165	6,377	7,165	10,432	9,838	8,751	15,602	12,913	10,468	13,895	12,218	13,905	12,198	14,524	14,735	12,198	17,980	18,174	16,852	16,483	17,696	16,859	16,640	16,370	15,641	13,681	13,115	12,626	12,882	13,191	12,405	12,807	13,229	12,766	12,498	14,600	15,700	14,600	14,500	21,500	17,000	17,300	14,900	21,000	18,000	16,700	16,600	17,300	15,000	14,800	12,300	13,300	12,100	-	7,000	0	0	0	0
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Selling General Administrative	15,992	14,656	11,287	10,855	31,131	17,445	14,585	18,180	17,736	12,718	14,711	12,617	30,082	15,020	10,069	9,264	10,277	9,525	10,994	11,088	11,163	9,633	9,294	7,643	7,749	7,032	6,549	7,322	6,626	6,305	6,863	6,825	6,190	4,971	7,225	5,994	5,598	6,742	5,239	5,072	4,420	4,756	4,306	4,502	4,283	4,382	3,940	3,503	2,999	4,110	3,855	4,180	4,418	18,968	3,290	3,048	18,256	2,415	2,831	6,817	3,206	5,929	4,551	10,099	3,871	4,856	7,516	14,167	156,548	31,861	35,710	166,099	27,534	26,656	27,115	26,955	26,656	24,391	23,625	21,203	21,808	13,216	13,571	12,426	10,976	10,766	10,279	9,658	8,178	7,206	8,886	10,157	8,176	8,560	9,572	7,792	7,200	6,000	8,200	5,900	6,700	3,800	3,300	2,800	2,700	2,500	2,600	2,300	2,900	2,100	2,600	0	0	-	-	0	0	0	0	0
Tax Provision	-1,091	-2,552	881	11,922	38,674	453	259	-4,755	-2,058	1,536	2,576	-12,342	-2,391	-4,911	6,033	-6,284	-810	-4,620	-3,609	176,376	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0	0	0	0	0
Total Operating Expenses	29,795	28,426	26,680	26,057	48,867	51,299	45,527	50,300	47,755	37,683	8,343	42,282	64,155	31,748	26,676	24,690	35,245	26,819	26,712	25,880	23,486	20,841	18,734	18,328	20,376	14,497	14,077	18,710	15,765	14,909	14,051	13,353	9,058	7,509	11,235	9,956	8,797	9,763	7,928	8,203	6,794	7,170	6,328	6,967	6,759	7,029	6,790	6,320	6,874	6,155	7,092	6,166	8,850	23,477	9,466	10,410	28,382	12,336	12,301	17,279	13,778	11,603	10,437	16,773	13,812	14,203	15,776	29,278	23,362	45,972	49,171	178,317	41,439	38,854	41,639	41,690	38,854	42,371	41,799	38,055	38,291	30,912	30,430	29,066	27,346	26,407	23,960	22,773	20,804	20,088	23,014	23,498	15,380	25,915	26,365	24,713	18,600	25,800	26,200	23,500	30,500	22,600	22,400	19,500	26,400	23,000	21,600	21,200	22,700	21,700	18,600	16,000	16,500	15,200	-	9,400	3,400	2,100	2,000	2,000
Total Other Income Expense Net	20,455	-18,563	3,118	41,331	44,239	-702	-2,076	-13,532	-16,416	3,823	-7,788	6,584	15,276	-10,081	25,263	-30,385	4,998	-13,116	-14,171	831,964	-74,683	61,590	36,096	20,876	2,315	-1,600	-4,715	-1,082	-12,294	-4,500	-11,343	-5,769	-5,422	1,272	17,709	-673	-3,187	-2,813	-253	-2,906	-4,618	-1,272	2,219	-1,739	-3,598	2,123	-1,998	243	1,006	-2,068	1,153	-1,111	1,587	4,188	3,858	1,545	-358	281	-260	-109	-72,280	336	-299	9	-871	590	502	51	146,362	-3,577	2,173	3,355	2,877	16,271	4,296	1,941	16,271	-240	-19	-13	-132	-263	-379	-5,318	4,023	-260	-329	-2,267	-7,614	-196	-52	-501	1,467	-393	-364	-1,534	-5,500	-200	0	0	-15,000	-28,000	0	0	-64,100	800	900	1,100	800	700	900	1,100	1,200	1,200	-	-1,300	-1,400	-1,300	-1,400	-1,300
Total Revenue	28,101	32,868	26,366	43,979	50,382	66,088	57,419	45,693	72,473	64,835	84,675	55,150	69,990	41,848	41,420	33,161	27,003	24,808	24,987	43,484	59,590	45,663	90,043	56,157	50,464	33,375	27,995	29,267	38,185	21,619	19,521	29,648	21,192	17,701	18,418	14,602	22,998	14,973	10,608	15,958	14,737	13,005	9,580	11,651	13,635	6,375	5,742	5,636	12,936	5,741	7,463	3,896	3,940	7,802	5,838	5,958	13,977	7,901	7,594	9,470	12,389	5,248	4,804	4,874	5,770	5,479	1,410	235	34,130	36,707	48,447	50,956	49,068	36,943	45,799	36,985	36,943	49,497	40,460	36,612	57,608	31,283	29,126	23,123	27,323	25,266	19,166	24,886	22,643	19,174	17,489	17,035	13,599	12,070	10,771	11,669	12,400	9,800	8,400	10,300	4,300	3,900	4,400	5,100	21,800	10,200	9,900	9,800	9,600	10,100	8,500	8,800	7,900	6,600	5,400	4,600	4,800	3,700	2,500	2,300

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	131,314
Cost of Revenue	-11,561
Gross Profit	119,753	119,753

Operating Income (+$)
Gross Profit	119,753
Operating Expense	-109,932
Operating Income	9,821	9,821

Operating Expense (+$)
Research Development	24,537
Selling General Administrative	52,790
Selling And Marketing Expenses	0
Operating Expense	109,932	77,327

Net Interest Income (+$)
Interest Income	7,041
Interest Expense	-656
Other Finance Cost	-109
Net Interest Income	6,276

Pretax Income (+$)
Operating Income	9,821
Net Interest Income	6,276
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	63,660	-44,018 EBIT - interestExpense = 14,924 61,995 52,810
Interest Expense	656
Earnings Before Interest and Taxes (EBIT)	15,580	64,316
Earnings Before Interest and Taxes (EBITDA)	51,223

After tax Income (+$)
Income Before Tax	63,660
Tax Provision	-49,606
Net Income From Continuing Ops	21,097	14,054
Net Income	52,154
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	121,493
Total Other Income/Expenses Net	53,839	-6,276

Technical Analysis of Ligand
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ligand. The general trend of Ligand is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ligand's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (28.6%)		Bearish trend (-28.6%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Ligand Pharmaceuticals Incorporated.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 94.57.

The bearish price targets are: 74.34 > 68.25 > 68.14.

Tweet this

Ligand Pharmaceuticals Incorporated Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ligand Pharmaceuticals Incorporated. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close > MA 100: The price is above the MA 100. +1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending down: The MA 200 is trending down. -1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Ligand Pharmaceuticals Incorporated Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ligand Pharmaceuticals Incorporated. The current macd is 1.22785611.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ligand price going down in the near term. -2
MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ligand. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ligand price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1

Ligand Pharmaceuticals Incorporated Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Ligand Pharmaceuticals Incorporated. The current adx is 21.87.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ligand shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.

Ligand Pharmaceuticals Incorporated Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ligand Pharmaceuticals Incorporated. The current sar is 81.68.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Ligand Pharmaceuticals Incorporated Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ligand Pharmaceuticals Incorporated. The current rsi is 40.45. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Ligand Pharmaceuticals Incorporated Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ligand Pharmaceuticals Incorporated. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH < 20: The STOCH %K is below 20 and oversold. -2
STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ligand price going down in the near term. -2
Trending down: The STOCH %K is trending down. -1

Ligand Pharmaceuticals Incorporated Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ligand Pharmaceuticals Incorporated. The current cci is -23.6744986.

Ligand Pharmaceuticals Incorporated Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ligand Pharmaceuticals Incorporated. The current cmo is -35.30564368.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Ligand Pharmaceuticals Incorporated Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Ligand Pharmaceuticals Incorporated. The current willr is -87.57170172.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1

Ligand Pharmaceuticals Incorporated Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ligand Pharmaceuticals Incorporated. The current atr is 2.74703162.

Ligand Pharmaceuticals Incorporated Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ligand Pharmaceuticals Incorporated. The current obv is 1,748,694.

Ligand Pharmaceuticals Incorporated Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ligand Pharmaceuticals Incorporated. The current mfi is 57.35.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

MFI > 50: +1

Ligand Pharmaceuticals Incorporated Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Ligand Pharmaceuticals Incorporated.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-11-30	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2023-12-04	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-06	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-07	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-11	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-29	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-01-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-03	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-08	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-09	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-17	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-01-19	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-22	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-01-24	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-25	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-01-29	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-09	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-13	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-15	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-20	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-02-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-23	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-27	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-28	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-29	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-04	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-05	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-11	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-19	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-25	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-26	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-28	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-01	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-04-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-03	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-04-04	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-04-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-18	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).

6.3. Candlestick Patterns

Ligand Pharmaceuticals Incorporated Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Ligand Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	40.446
Ma 20	Greater than	Ma 50	75.973
Ma 50	Greater than	Ma 100	75.228
Ma 100	Greater than	Ma 200	72.118
Open	Greater than	Close	78.700
Total			4/5 (80.0%)

Create your own Symbol Scanner

Get notifications about Ligand Pharmaceuticals Incorporated

I send you an email if I find something interesting about Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated Buy, Hold or Sell?

Let's analyse Ligand together

Get notifications about Ligand Pharmaceuticals Incorporated

Quick analysis of Ligand (30 sec.)

What can you expect buying and holding a share of Ligand? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Ligand (5 min.)

$72.52

$39.67

$-81.74 - $-18.54

$-42.07 - $21.13

2. Growth of Ligand (5 min.)

Is Ligand growing?

How much money is Ligand making?

How much money comes from the company's main activities?

3. Financial Health of Ligand (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Ligand? (5 min.)

What can you expect buying and holding a share of Ligand?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Ligand

About Ligand Pharmaceuticals Incorporated

Financial Health

Valuation

1.1. Profitability of Ligand Pharmaceuticals Incorporated.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Ligand Pharmaceuticals Incorporated.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Ligand Pharmaceuticals Incorporated.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Ligand Pharmaceuticals Incorporated.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Ligand Pharmaceuticals Incorporated

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Ligand Pharmaceuticals Incorporated
Buy, Hold or Sell?